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The adverse effects of smoking have fostered a natural market for
smoking cessation and smoking reduction products. Smokers attempting to
quit or reduce consumption have tried everything: "low" or "light"
cigarettes; nicotine-infused chewing gum, lozenges, and lollipops; dermal
patches; and even hypnosis. The latest craze in the quest to find a safer
source of nicotine is the electronic cigarette. Electronic cigarettes (e-
cigarettes) have swept the market, reaching a rapidly expanding
international consumer base. Boasting nicotine delivery and the tactile feel
of a traditional cigarette without the dozens of other chemical constituents
that contribute to carcinogenicity, e-cigarettes are often portrayed as less
risky, as a smoking reduction or even a complete smoking cessation product,
and perhaps most troubling for its appeal to youth, as a flavorful, trendy, and
convenient accessory.
The sensationalism associated with e-cigarettes has spurred outcry from
health and medical professional groups, as well as the Food and Drug
Administration (FDA), because of the unknown effects on public health.
Inhabiting a realm of products deemed "tobacco products" under recent
2009 legislation, e-cigarettes pose new challenges to FDA regulation
because of their novel method of nicotine delivery, various mechanical and
electrical parts, and nearly nonexistent safety data. Consumer use, marketing
and promotional claims, and technological characteristics of e-cigarettes
have also raised decades old questions of when the FDA can assert authority
over products as drugs or medical devices. Recent case law restricting FDA
enforcement efforts against e-cigarettes further confounds the distinction
among drugs and medical devices, emerging e-cigarette products, and
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traditional tobacco products such as cigarettes, cigars, and smokeless
tobacco.
This Article investigates the e-cigarette phenomenon in the wake of the
recently enacted Family Smoking Prevention and Tobacco Control Act of
2009 (TCA). It examines the tumultuous history of attempts at tobacco
regulation by reflecting on the history of Congressional activity to regulate
tobacco sales and promotion. Furthermore, this Article suggests a feasible
approach to strengthening regulation of e-cigarettes under the existing
statutory framework. This approach includes increased scrutiny of
manufacturer and distributor claims that trigger drug and medical device
provisions, utilization of new tobacco product and modified risk tobacco
product provisions, and promulgation of new FDA regulations and guidance
specifically directed at e-cigarettes.
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INTRODUCTION
The American public conscience has wrestled with knowledge of the
adverse effects of smoking for decades, perpetuating an embattled division
in the United States between smokers (and those who believe smoking is a
personal freedom) and non-smokers (and those who believe that the public
health risks and resulting health care costs outweigh personal freedom
arguments). In response to the negative health effects of tobacco products
and cigarettes in particular, a natural market for smoking cessation and
smoking reduction products has emerged over the last 30 years. Those
attempting to quit or reduce consumption have tried everything: "low" or
"light" cigarettes; nicotine-infused chewing gum, lozenges, and lollipops;
dermal patches; and even hypnosis. Regardless of one's position on the
personal freedom argument, smoking is not only dangerous to health, it is an
addiction-the human body becomes dependent on nicotine through a
variety of mechanisms.
The latest craze in the quest to find a "safer" source of nicotine is the
electronic cigarette. Electronic cigarettes (e-cigarettes) have swept the
market, reaching a rapidly expanding international consumer base. They are
composed of three basic standardized parts: the nicotine cartridge; the
atomizer, which vaporizes the nicotine; and the battery that powers it.'
Boasting the tactile feel of a traditional cigarette and rapid nicotine delivery
without the dozens of other chemical constituents that contribute to the
carcinogenicity of traditional cigarettes and cigarette smoke,2 e-cigarettes
are often portrayed as "safer" than traditional cigarettes, as a smoking
reduction or even a complete smoking cessation product, and perhaps most
troubling for its appeal to youth, as a flavorful, trendy, and convenient
accessory.
The broad appeal of e-cigarettes is skyrocketing given the now
incontrovertible scientific evidence of the destructive impacts of smoking on
public health, including a consistent statistic that smoking accounts for
I Tobacco Fact Sheet: Electronic Cigarettes (E-Cigarettes), Legacy for Longer Healthier
Lives, http://www.legacyforhealth.org/content/download/582/6926/version/4/file/FactSheet-
eCigarettes.pdf (last updated Dec. 2012).
2 U.S. Surgeon Gen., A Report of the Surgeon General: How Tobacco Smoke Causes
Disease-The Biology and Behavioral Basis for Smoking-Attributable Disease Fact Sheet,
U.S. Dep't Health & Human Servs.,
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nearly 5.4 million cancer-related deaths worldwide each year,3 including
approximately 443,000 in the United States.4 The attraction to e-cigarettes
crosses many segments of the population: the heavy smoker wanting to quit
or significantly cut back on cigarettes or nicotine use, the occasional smoker
seeking a healthier alternative, the smoker seeking a legal way to get a
nicotine fix in public places with smoking bans, the non-smoker who wants
to try e-cigarettes for the nicotine without the harmful additives, and even
the young hipster who wants to complete her technological portfolio with a
sleek and popular device that looks and feels like a real cigarette, but brings
with it an "atomizer" and celebrity endorsements. The use of e-cigarettes is
on the rise-with group identity to "vaping"' 5-and is becoming a strong
presence in various social media outlets and easy product purchasing online
through distributors and affiliates or at convenience stores and retail
establishments.
However, the sensationalism associated with e-cigarettes has spurred
outcry from health and medical professional groups, as well as the Food and
Drug Administration (FDA), because of the unknown effects on public
health and an absent safety profile. Inhabiting a realm of products deemed
"tobacco products" under recent 2009 legislation and subsequent case law,
e-cigarettes pose new challenges to FDA regulation because of their novel
method of nicotine delivery, various mechanical and electrical parts, and
nearly nonexistent safety data. Consumer use, marketing and promotional
claims, and technological characteristics of e-cigarettes have also raised
decades-old questions of when the FDA can assert authority over products
as drugs or medical devices.
In the wake of the recently enacted Family Smoking Prevention and
Tobacco Control Act (TCA), it is urgent to examine the scope and
limitations of the legislative provisions as applied to the recent phenomenon
of e-cigarettes. This Article will argue that the recent 2010 D.C. Circuit case
Sottera, Inc. v. FDA7 has hindered FDA attempts to regulate products that
3 Tobacco Free Initiative: Tobacco Facts, WHO, http://www.who.int/tobacco/mpower/
tobaccofacts/en/index.html (last visited Apr. 5, 2013).
4 CDC, Current Cigarette Smoking Among Adults-United States, 2011, 309 JAMA
539, 539-40 (2013).
5 Users refer to the process of vaporizing the nicotine within the electronic cigarette as
"vaping." See, e.g., Linda Hurtado, Some Say "Vaping" E-Cigarettes is Worse Than
Smoking the Real Thing, ABC News (Aug. 16, 2011),
http://www.abcactionnews.com/dpp/news/health/some-say-vaping-e-cigarettes-is-worse-
than-smoking-the-real-thing.
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fall outside the traditional realm of cigarettes and smokeless tobacco,
thwarting Congressional purpose and introducing the potential for
significant future public harm. However, despite the Sottera decision, the
FDA retains powers to proceed against e-cigarettes, including drug and
medical device provisions within the Food, Drug, and Cosmetic Act
(FDCA), tobacco product provisions of the TCA (integrated into the FDCA)
regarding new tobacco products and modified-risk tobacco products, and
authority to promulgate product-specific regulations.
This Article does not condemn e-cigarettes, but propels the regulatory
discussion forward. The Article proceeds in six parts, providing both a
descriptive and prescriptive analysis of the FDA authority to regulate e-
cigarettes after Sottera. Part I briefly examines fundamental issues of
smoking, nicotine addiction, and the public health. Part II examines the
tumultuous history of attempts at tobacco regulation by reflecting on the
history of Congressional activity to regulate tobacco advertising and
promotion, and particularly the monumental 2000 Supreme Court decision
FDA v. Brown & Williamson Tobacco Co., 8 which struck down the FDA's
assertion of jurisdiction over cigarettes using drug and medical device
frameworks. Part III analyzes the legislative provisions and overarching
authority imparted to the FDA over tobacco products contained in the TCA.
Part IV examines e-cigarettes and industry characteristics, various marketing
and promotional tactics, public perceptions about the products, and public
health perspectives and scientific studies. Part V examines the culmination
of the FDA's attempts to regulate e-cigarettes in Sottera and highlights its
present position on jurisdiction over these products. Part VI suggests a
feasible approach for strengthening FDA regulation of e-cigarettes. The Part
also discusses the importance of the scope of intent and intended use in
marketing and advertising of the FDCA, the application of the drug and
device provisions of the FDCA and the new product and modified-risk
product provisions of the TCA, and the opportunity for the development of
product-specific requirements through FDA regulations and guidance.
I. ADDICTION, NICOTINE, AND THE PUBLIC HEALTH
Scientists, health and medical professionals, regulators, policymakers,
health advocates, and various other stakeholders have devoted tomes to the
health effects of smoking and use of tobacco products. The Centers for
Disease Control and Prevention (CDC) report that smoking costs the United
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States an estimated $96 billion annually in direct medical expenses and an
additional $97 billion in lost productivity.9 This Article does not endeavor to
reprise that literature, but only to touch on foundational theories of nicotine
addiction and public health. The arguments contained in the Article stem
from the position that nicotine itself is a dangerous substance because of its
addictive qualities. Efforts to temper current cigarette and tobacco use
should be encouraged; therefore, e-cigarettes may be less harmful for heavy
or moderate smokers because they may reduce exposure to carcinogens and
other toxic chemicals that cause serious disease and death. However, any
use of products that contain pure nicotine 0 is potentially harmful based on
theories of addiction and dependence. There are a multitude of risks that
deserve consideration when contemplating appropriate regulation including
the need for premarket assessment for product safety, restrictions on access,
appropriate scope of advertising and promotion, and assurance of truthful
and non-misleading labeling of such products.
Among other reasons, smokers smoke for the nicotine. Nicotine
addiction is characterized as a form of drug dependence recognized in the
current edition of the American Psychological Association's Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV)." The most common
form of nicotine delivery is the cigarette, which contains hundreds of toxic
chemicals-69 of which have been found to cause cancer.12 Tobacco smoke
itself is a human carcinogen.' 3 The cigarette (or cigar, cigarillo, or smokeless
tobacco) is merely a conduit, a delivery vehicle for the nicotine contained
within the tobacco. Aside from the carcinogenic and toxic effects of
tobacco, smokers become addicted to the nicotine.14
9 CDC, Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity
Losses-United States, 2000-2004, 57 MORBITY & MORTALITY WKLY. REP., 1226, 1226-28
(2008).
10 The products contain other ingredients as well, including propylene glycol, ethanol,
glycerol (glycerin), acetylpyrazine, guaiacol, myosmine, and cotinine. See, e.g., FAQs,
NJOY, http://www.njoy.com/pages/FAQs.html (last visited Apr. 5, 2013).
AM. PSYCHOLOGICAL Ass'N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL
DISORDERS: DSM-IV-TR (4th ed. text rev. 2000); see, e.g., Neal L. Benowitz, Neurobiology
of Nicotine Treatment Addiction: Implications for Smoking Cessation Treatment, 121 AM. J.
MED., at S3, S4 (Supp. 2008); Caroline Cohen et al., CBJ Receptor Antagonists for the
Treatment of Nicotine Addiction, 81 PHARMACOLOGY BIOCHEMISTRY & BEHAV. 387, 388
(2005).
12 U.S. Surgeon Gen., supra note 2.
13 Id.
See generally, Neal L. Benowitz, Nicotine Addiction, 362 NEw ENG. J. MED. 2295
(2010); John A. Dani & Steve Heinemann, Molecular and Cellular Aspects of Nicotine
333
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Decades of research identify the neural and pharmacologic basis of
nicotine addiction induced by smoking. Inhaled smoke carries nicotine into
the lungs where it is absorbed and enters arterial circulation.' 5 It then flows
into the brain, where it binds to nicotinic cholinergic receptors and releases
various neurotransmitters.16 Dopamine, a monoamine neurotransmitter,
signals pleasure to the user, while also simultaneously reducing stress and
anxiety.17 "[N]icotine addiction is a combination of positive reinforcements,
including enhancement of mood and avoidance of withdrawal symptoms."' 8
Conditioning has a secondary role in nicotine addiction: smokers associate
particular cues (e.g., social situations, environmental factors, moods) with
the high of smoking, often causing relapse when those seeking to quit
smoking are confronted with those cues.19
Society generally imparts an assumption of risk and right of personal
choice on the person using potentially harmful products such as illicit drugs,
alcohol, and other common vices.2 0 However, smoking introduces
measurable harmful effects on third parties exposed to secondhand smoke.2 1
Smoking bans and restrictions on use are directed at curbing this
secondhand exposure to tobacco smoke in public places and workplaces.
Recent studies have also begun to highlight lingering "thirdhand" smoke
that remains as residue in carpeting, walls, and other structures for up to 30
years and is potentially toxic, particularly to children climbing, crawling, or
playing in or on the contaminated areas.22
While nicotine use and addiction have long been linked to tobacco use
and smoking of traditional tobacco products such as cigarettes, cigars, and
Abuse, 16 NEURON 905 (1996); Dorothy K. Hatsukami et al., Tobacco Addiction, 371
LANCET 2027 (2008); Steven R. Laviolette & Derek van der Kooy, The Neurobiology of
Nicotine Addiction: Bridging the Gap from Molecules to Behaviour, 5 NATURE REV.
NEUROSCIENCE 55 (2004).
15 Benowitz, supra note 14, at 2295.
16 Id. at 2295-96.
17 Id. at 2298.
18 Id.
Id.
20 See, e.g., Jim Leitzel, Regulating Vice: Misguided Prohibitions and Realistic Controls
3-10 (2008); Smoking: Risk, Perception & Policy (Paul Slovic ed., 2001).
21 Unfiltered: Conflicts over Tobacco Policy and Public Health 21-27 (Eric A. Feldman
& Ronald Bayer eds., 2004).
22 Ware G. Kuschner et al., Electronic Cigarettes and Thirdhand Tobacco Smoke: Two
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smokeless tobacco, e-cigarettes are raising similar health and safety
considerations. One attraction to e-cigarettes is that they do not bum tobacco
and other harmful chemicals, but instead vaporize nicotine into a fine mist
that is inhaled by the user. As discussed in Part IV, however, these products
may directly pose a health threat to users given the available levels of
nicotine, the lack of cues that serve to signal the end of a typical cigarette,
and the potential for electrical components in the products to malfunction.
E-cigarette cartridges contain up to twenty times the nicotine of a single
cigarette, and the process of vaping lacks the normal cues associated with
cigarette completion, such as the butt of the cigarette ending a dose.23
Furthermore, e-cigarettes are manufactured from metal and ion components
that introduce concerns about faulty products and malfunctions. The
research on whether vaping e-cigarettes has a detrimental secondhand effect
is currently inconclusive; state and local restrictions on e-cigarette use are
driven largely by the concern that they have similar damaging effects on
bystanders as traditional cigarettes.
Together with general safety concerns, e-cigarettes also have a different
risk profile than traditional cigarettes. Although the risks of e-cigarette use
are likely less than traditional cigarettes for heavy or moderate smokers, e-
cigarettes may also attract regular users who otherwise were social smokers
or non-smokers. Measures of a product's overall safety are driven by a risk-
benefit analysis: heavy or moderate smokers (and those exposed to their
secondhand smoke) would benefit from reducing or eliminating the risks of
cigarette use (including lung cancer, heart attack, stroke, adverse pregnancy,
and sudden death).24 Yet those who would not smoke a cigarette, and
vulnerable populations such as youth and adolescents, carry a different risk
profile. Non-smokers or social smokers who begin using e-cigarettes are
exposed to the addictive qualities of nicotine and possible other harmful
chemicals present in trace amounts. In addition to the compelling likelihood
of e-cigarettes supporting or inducing nicotine addiction in users, and
possibly serving as a gateway product for subsequent cigarette use, these
products raise a host of potential health and safety problems that have yet to
be fully explored.
335
23 See infra Part IV.C.
24 U.S. Surgeon Gen., supra note 2.
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II. THE HISTORY OF TOBACCO REGULATION AND THE LEGACY OF FDA V.
BROWN & WILLIAMSON TOBACCO CO.
A. The Awakening
The tobacco industry has enjoyed a spectacular run. As a longstanding
cash crop in the United States and abroad, tobacco leaves and their products
have long thrived in the marketplace. Historical research reveals that
tobacco has been cultivated since 5000 BC and was widely used in the
Americas by the time Columbus reached their shores in 1492.25 Prior to
scientific advancements in toxicology and carcinogen research, little was
known about the constituents comprising tobacco products sold primarily in
the form of rolled cigars and cigarettes, chewing snuff, and pipe tobacco. It
was not until the U.S. Surgeon General's declaration in 1957 that a causal
connection had been discovered between smoking and lung cancer that the
adverse health effects of smoking began to confront the American public.26
In 1964, the Surgeon General's subsequent Smoking and Health report
presented striking statistics supporting the position that smoking was a
leading cause of preventable death. 27 Data indicated that by 1964 there had
already been 12 million premature deaths attributable to smoking in the
United States alone.28 Subsequent data released in federal government
reports revealed a definitive link between nicotine dependence and
neurological chemistry of the brain, with addictive effects similar to those of
heroin and cocaine.29
Shortly after the 1964 report, Congress began enacting legislation
restricting various aspects of tobacco industry labeling and advertising
practices. Six core statutes were enacted by Congress between 1965 and
2000: the Federal Cigarette Labeling and Advertising Act (FCLAA) of
1965; o the Public Health Cigarette Smoking Act of 1969;31 the Alcohol and
25 Arthur W. Musk & Nicholas H. De Klerk, History of Tobacco and Health, 8
RESPIROLOGY 286,286 (2003).
26 The Reports of the Surgeon General: Brief History, NAT'L LIBRARY MED.,
http://profiles. nlm.nih.gov/ps/retrieve/Narrative/NN/p-nid/58 (last visited Apr. 5, 2013).
27 Advisory Comm., U.S. Dep't of Health, Educ. & Welfare, Smoking and Health
(1964).
28 Cancer Facts and Figures 2010, AM. CANCER Soc'y 42 (2010),
http://www.cancer.org/ acs/groups/content/@nho/documents/document/acspc-024113.pdf.
29 Office of the Surgeon Gen., U.S. Dep't of Health & Human Servs., The Health
Consequences of Smoking: Nicotine Addiction 6-9, 145-239 (1988).
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Drug Abuse Amendments of 1983;32 the Comprehensive Smoking
Education Act of 1984;33 the Comprehensive Smokeless Tobacco Health
Education Act of 1986;34 and the Alcohol, Drug Abuse, and Mental Health
Administration Reorganization Act of 1992.3' These statutes did not ban or
limit cigarettes and smokeless tobacco products, but only restricted
particular aspects of industry representations in order to ensure that
consumers were aware and informed of the adverse health effects. 3 6
Faced with increasing evidence of smoking's ill effects, health care
professionals and consumer safety groups submitted various citizens'
petitions to the FDA urging the agency to regulate cigarettes and tobacco
products based on its overriding public health mission to protect consumers
from unsafe products. As data accumulated over the next several decades,
so did demands (and petitions) for FDA action. Despite the mounting
evidence of the dangers of smoking, FDA Commissioners throughout the
end of the 2 0 th century continued to deny these petitions and to toe the line
that they lacked the authority to regulate. 39
B. Commissioner Kessler's 1996 Regulations
Former FDA Commissioner David Kessler announced a new position in
August 199640 in an effort to remedy FDA inaction in the face of a public
health epidemic brought about by smoking and secondhand smoke. Through
the process of notice and comment rulemaking, the FDA issued two final
rules asserting jurisdictional authority over tobacco products on the basis
Public Health Cigarette Smoking Act, Pub. L. No. 91-222, 84 Stat. 87 (1969).
32 Alcohol and Drug Abuse Amendments, Pub. L. No. 98-24, 97 Stat. 175 (1983).
3 Comprehensive Smoking Education Act, Pub. L. No. 98-474, 98 Stat. 2200 (1984).
3 Comprehensive Smokeless Tobacco Health Education, Pub. L. No. 99-252, 100 Stat.
30 (1986).
3 Alcohol, Drug Abuse, and Mental Health Administration Reorganization Act, Pub. L.
No. 102-321, 106 Stat. 394 (1992).
36 For a detailed description of the scope and chronology of these statutes, see FDA v.




40 Supreme Court precedent confirms the ability of an agency to change a position
relating to statutory interpretation, no matter how long-standing, as long as it supplies a
reasoned analysis and the new position conforms to the statute. See Motor Vehicle Mfrs.
Assoc. v. State Farm Mutual Auto. Ins. Co., 463 U.S. 29 (1983).
337
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that nicotine is a drug 4' and classifying cigarettes and smokeless tobacco as
combination drug and medical device products, 42 triggering premarket
safety and efficacy requirements provided in the FDCA. This was a
controversial move, to say the least.
The FDCA is the voluminous statute granting the FDA jurisdictional
authority over various products, including food, cosmetics, animal and
human drugs, medical devices, and radiological products.43 Drugs are
defined in the FDCA as (A) articles recognized in the official United States
Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States,
or official National Formulary, or any supplement to any of them; and (B)
articles intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease in man or other animals; and (C) articles (other than
food) intended to affect the structure or any function of the body of man or
other animals; and (D) articles intended for use as a component of any
article.44
A device is similarly defined by its intended use, as an instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent, or
other similar or related article, including any component, part, or accessory,
which is- (1) recognized in the official National Formulary, or the United
States Pharmacopeia, or any supplement to them, (2) intended for use in the
diagnosis of disease or other conditions, or in the cure, mitigation, treatment,
or prevention of disease, in man or other animals, or (3) intended to affect
the structure or any function of the body of man or other animals, and which
does not achieve its primary intended purposes through chemical action
within or on the body of man or other animals and which is not dependent
upon being metabolized for the achievement of its primary intended
purposes. 45
Kessler reasoned that because nicotine was an addictive substance
affecting the "structure or function of the body" and had significant
41 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,396, 44,419 (Aug. 28, 1996)
(to be codified in scattered sections of21 C.F.R.).
42 Id. at 44,396-44,618. The proposed rule was published in August 1995. Regulations
Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco Products to
Protect Children and Adolescents, 60 Fed. Reg. 41,314 (Aug. 11, 1995).
43 Food, Drug, and Cosmetic Act (FDCA), Pub. L. No. 75-717, 52 Stat. 1040 (1938)
(codified with some differences in language at 21 U.S.C. §§ 301-399f (2006)).
44 21 U.S.C. § 32 1(g) (2006).
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pharmacological effects, it fell under the FDA's statutory authority46 as a
drug47 and, furthermore, cigarettes and smokeless tobacco were delivery
devices. 48 The FDA deemed the "psychoactive, or mood-altering, effects on
the brain"49 "intended"o for purposes of the FDCA because they "are so
widely known and foreseeable"51 that manufacturers have deliberately
designed cigarettes to provide these effects to consumers. 52
Based on its newly announced jurisdictional authority, the FDA
promulgated a 223-page final rule targeted toward reducing tobacco
consumption among children and adolescents. The regulations focused on
labeling, promotion, and access to cigarettes and smokeless tobacco by
children and adolescents. Provisions included age and photo identification
requirements for purchase, prohibitions on free samples, prohibitions on
promotional items bearing a brand name, prohibitions on purchases by
means of self-service displays or vending machines (except in adult
establishments), restrictions on print advertisements to black and white text
only, limitations on outdoor advertising near public schools or playgrounds,
and prohibitions on brand name sponsorship.54 The rulemaking has been
described as the longest in FDA history with 700,000 comment submissions
received during the course of agency considerations.5
The final rule further required cigarette and smokeless tobacco
46 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,631. This position utilizes
the definition of drug as a product "intended to affect the structure or function of the body."
21 U.S.C. §321(g) (Supp. 2011).
4 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,397.
48 Id. at 44,402.
Id. at 44,631-32.
50 Intent and intended use is the underlying trigger for drug regulation under the FDCA.
See infra Part IlI.B.
5 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,687.
52 Id.
53 Id. at 44,418.
54 Id. at 44,396.
CTR. FOR TOBACCO PRODS., U.S. DEP'T OF HEALTH & HUMAN SERVS., COMPLIANCE
WITH REGULATIONS RESTRICTING THE SALE AND DISTRIBUTION OF CIGARETTES AND SMOKELESS
TOBACCO TO PROTECT CHILDREN AND ADOLESCENTS [REVISION TO DRAFT GUIDANCE] 2 (2011)
(citing 155 Cong. Rec. S6407 (June 10, 2009) (statement of Sen. Kennedy)).
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manufacturers to submit reports of adverse events to the FDA.56 The FDA
indicated that this regulatory scheme would "achieve[] the best public health
result for these products."57
While many health professionals lauded the regulations, the FDA was
simultaneously rebuked for not going far enough to remove the products
from the market.' 8 Citing the touchstone risk-benefit assessment
underpinning its decisions regarding safety59 in the drug and medical device
realm, 60 the FDA emphasized that due to the potential for consumer
withdrawal and large-scale addiction treatment needs, as well as the likely
emergence of a black market for banned products, it would closely assess,
though not entirely ban, tobacco.6 1
The change in agency position provoked extensive criticism from the
tobacco industry. A consortium of tobacco manufacturers, retailers, and
advertisers swiftly filed suit alleging that the FDA lacked the jurisdiction to
regulate tobacco products, that the FDA did not have authority to
promulgate the regulations under the FDCA,62 and that the restrictions on
56 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,615.
57 Id. at 44,413.
58 See, e.g., Shankar Vedantam, Clinton Clamps Down on Tobacco, FRESNO BEE,
August 24, 1996, at Al.
59 While the term "safety" is never defined within the FDCA, the FDA has interpreted it
to be based on a risk-benefit assessment, where a product's benefits must outweigh its risks
in order for it to be approved to enter the market. The FDA evaluates new drugs based on
information provided in the New Drug Application, including the clinical trial data, intended
use, patient population, dosage and administration, adverse effects, contraindications, etc. An
FDA Commissioner has described the inquiry into risk as depending on a variety of factors,
including "[t]he interaction of the drug with body processes," "[tihe manner in which the
drug is absorbed, distributed in body tissues, and excreted," "[w]hether active compounds
arise from the metabolism of the drug by the body," [tihe influence of other chemicals, such
as other drugs or even articles of food or drink upon the activity of the drug in question," and
"how the activity of the drug in animals compares with its activity in man." Drug Safety:
Hearings Before a Subcomm. of the H. Comm. on Gov't Operations, 88th Cong. 566 (1964)
(testimony of George Larrick, Comm'r, FDA).
60 Requirements for drugs and medical devices and the combination product paradigm
are detailed elsewhere. See, e.g., Jordan Paradise, Reassessing Safety for Nanotechnology
Combination Products: What Do Biosimilars Add to Regulatory Challenges for FDA?, 56 ST.
Louis L. J. 465,478-90,494-96 (2012).
61 Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at 44,398.
62 The FDA had asserted authority to promulgate regulations under 21 U.S.C. §360j,
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advertising violated the First Amendment. The Fourth Circuit held that
Congress had not granted jurisdiction to the FDA to regulate tobacco
products, thereby bringing an abrupt end to the FDA's short-lived victory
over the tobacco industry.
C. Cigarettes and the Supreme Court
The Supreme Court affirmed the Fourth Circuit in a 5-4 decision in
FDA v. Brown & Williamson Tobacco Co.65 holding that Congress had
clearly "intended to exclude tobacco products from the FDA's
jurisdiction." 66 Invoking Chevron U.S.A. v. Natural Resources Defense
Council,6 7 the Court gave no deference to the FDA's 1996 final rules and
instead divined a congressional intent to exclude tobacco products from
FDA jurisdiction: "reading the FDCA as a whole, as well as in conjunction
with Congress' subsequent tobacco-specific legislation, it is plain the
Congress has not given the FDA the authority to regulate tobacco products
as customarily marketed."6
Crucial to Justice O'Connor's majority opinion was the fact that the
FDCA was enacted on the premise that all drugs and devices overseen by
the FDA must satisfy hurdles of both safety and efficacy requirements
before entering the market. O'Connor reasoned that, given the scientific
evidence linking smoking to cancer and other health risks, the danger
inherent in cigarettes would necessitate that the FDA remove them
completely from the market, a result that Congress surely did not intend.
of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. at
44,399.
63 Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374 (M.D.N.C. 1997), rev'd sub nom.
Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir. 1998), affd, 529 U.S.
120 (2000). The district court held that the FDA had authority to regulate tobacco products
and to promulgate regulations regarding labeling and access, but that the promotion and
advertising restrictions contained within the regulations exceeded statutory authority. Id. at
1380-1400.
Brown & Williamson, 153 F.3d 155. The court did not reach First Amendment
questions.
65 529 U.S. 120.
66 Id. at 121.
67467 U.S. 837 (1984). This case sets forth an analytical framework for courts regarding
deference to federal administrative agencies in the interpretation of statutes that they
administer.
68 Brown & Williamson, 529 U.S. at 161.
69 Id. at 121-22.
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The decision states,
[i]n its rulemaking proceeding, the FDA quite exhaustively documented that
tobacco products are unsafe, dangerous, and cause great pain and suffering
from illness. These findings logically imply that, if tobacco products were
"devices" under the FDCA, the FDA would be required to remove them
from the market under the FDCA's misbranding . . . and . . . device
* 70classification ... provisions.
A powerful dissent trails the majority opinion, highlighting both the
basic purpose and the literal language of the FDCA together with the
compelling evidence linking cigarettes to pharmacological addiction. In his
dissent, Justice Breyer (joined by Justices Stevens, Souter, and Ginsburg)
argues:
Cigarettes achieve their mood-stabilizing effects through the interaction of
the chemical nicotine and the cells of the central nervous system. Both
cigarette manufacturers and smokers alike know of, and desire, that
chemically induced result. Hence, cigarettes are "intended to affect" the
body's "structure" and "function," in the literal sense of these words.7 1
After the decision, the FDA withdrew the regulations.
Brown & Williamson is infamous not only for its outcome, but also for
the strained and tortuous application of the legendary two-step test first
espoused in Chevron7 2 to determine whether a court should afford deference
to an administrative agency decision interpreting a statute that it
administers.7 3 The Brown & Williamson decision examined the unique
history of tobacco including the multitude of statutory schemes and federal
agencies charged with particular aspects of tobacco regulation, the FDA's
70 Id. at 121.
71 Id. at 162 (Breyer, J., dissenting).
72 467 U.S. 837. Chevron involved regulations promulgated by the Environmental
Protection Agency (EPA) under the authority of the Clean Air Act of 1977. By regulation, the
EPA set forth a definition of a "source" of air pollution, which was upheld by the Court as a
permissible reading of the statute. Id. at 840, 866.
These two steps are: (1) whether Congress has directly spoken on the precise question
at issue in front of the court (i.e., is the statute unambiguous?); and (2) if the statute is silent
or ambiguous, the court will defer to the agency's reasonable or permissible interpretation of
the statute. If the statute is determined unambiguous at step 1, the court will apply plain
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past stance that it did not have authority to regulate tobacco products, and
the broad framework of the FDCA, to conclude that the FDA lacked
jurisdiction. The Court provided "[t]his is hardly an ordinary case" and that
tobacco has "a unique place in American history and society" and "its own
unique political history." 74  In essence, the Court utilized the
"extraordinary"" history of tobacco rather than consulting the language of
the FDCA to conclude that Congress had unambiguously spoken on the
issue of whether the FDA had authority over tobacco products, and had
resoundingly rejected jurisdiction through other means outside the FDCA
itself.76
III. CONGRESSIONAL RESPONSE: THE FAMILY SMOKING PREVENTION AND
TOBACCO CONTROL ACT OF 2009
Congress eventually provided the FDA with the requisite jurisdiction
and authority to regulate tobacco products. Nine years after Brown &
Williamson, Congress amended the FDCA and the FCLAA by enacting the
Family Smoking Prevention and Tobacco Control Act of 2009 (TCA).77
Signed into law by President Obama in July 2009, the TCA inserts a
substantial new chapter codified within the FDCA, which grants the FDA
sweeping oversight and enforcement authority over tobacco products,
including cigarettes and smokeless tobacco.78 Thus, the TCA supplements
the FDCA statutory scheme rather than supplanting it.
The wide-ranging legislation creates a new Center for Tobacco
Products (CTP) within the FDA,79 requires manufacturers to register their
Brown & Williamson, 529 U.S at 159-60.
Jack M. Beermann, End the Failed Chevron Experiment Now: How Chevron Has
Failed and Why It Can and Should Be Overruled, 42 CONN. L. REV. 779, 821 (2010).
76 For further analysis and discussion of the case, see Elizabeth Brown Alphin, Federal
Tobacco Regulation: The Failure of FDA Jurisdiction Over Tobacco and the Possibility of
Compromise Through a Congressional Scheme, 40 BRANDEIS L. J. 121 (2001); Joseph A.
Fazioli, Chevron Up in Smoke?: Tobacco At the Crossroads of Administrative Law, 22
HARV. J.L. & PUB. Pot'Y 1057 (1999); Marguerite M. Sullivan, Brown & Williamson v.
FDA: Finding Congressional Intent Through Creative Statutory Interpretation-A Departure
From Chevron, 94 Nw. U. L. REV. 273 (1999); and Roseann B. Termini, The Legal Authority
of the United States Food and Drug Administration To Regulate Tobacco: Calling on
Congress, 74 ST. JOHN'S L. REv. 63 (2000).
Pub. L. No. 111-31, 123 Stat. 1776 (codified in scattered sections of 5 U.S.C., 15
U.S.C. and 21 U.S.C. (2006)).
78 See infra Part III.A & B.
7921 U.S.C. § 387a(e) (2006).
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products,o mandates adherence to manufacturing practice requirements,8 '
requires disclosure to FDA of ingredients for all tobacco products, 82 grants
the FDA authority to establish product standards,83 permits the FDA to
reduce nicotine (though not eliminate it) and other harmful ingredients, 84
bans misleading descriptors without substantiation,85 enlarges tobacco
product warning labels and requires graphic images on packaging, 86 and
bans fruit and candy flavorings in cigarettes (although menthol is subject to
further scientific study rather than an outright ban).8 7 The FDA has since
taken steps to implement the TCA, including issuing multiple guidance
documents for industry.
Several aspects of the TCA are particularly relevant to a discussion of
e-cigarettes: the evident foundational concern from Congress regarding
youth and adolescent tobacco use that emerges from the legislative history
preamble; the scope of requirements for both new tobacco products and
modified-risk tobacco products; and the statutory implications of the
therapeutic claims made by manufacturers or distributors.
A. Congressional Goals and Legislative History
Congress was undeniably focused on protecting youth and adolescents
from the powerful advertising and marketing force of the tobacco industry.
The TCA enumerates 49 findings of Congress-21 of which specifically
address the impact and effects of smoking and tobacco marketing on youth
80 Id. § 387e.
81 Id. § 387e(e).
82 Id. § 387d.
83 Id. § 387g.
84 Id. § 387g(d)(3).
85 Id. § 387k.
8 6 Id. § 1333.
87 Id. § 387g.
88 See, e.g., CTR. FOR TOBACCO PRODS., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
REPORTING HARMFUL AND POTENTIALLY HARMFUL CONSTITUENTS AND TOBACCO SMOKE
UNDER SECTION 904(A)(3) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT (2012)
[hereinafter REPORTING HARMFUL CONSTITUENTS]; CTR. FOR TOBACCO PRODS., U.S. DEP'T OF
HEALTH & HUMAN SERVS., REGISTRATION AND PRODUCT LISTING FOR OWNERS AND
OPERATORS OF DOMESTIC TOBACCO PRODUCT ESTABLISHMENTS (2009) [hereinafter
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and adolescents.89 In fact, the second identified purpose of the TCA is "to
ensure that the Food and Drug Administration has the authority to address
issues of particular concern to public health officials, especially the use of
tobacco by young people and dependence on tobacco." 90 The legislation
expressly calls for the reintroduction of the 1996 FDA regulations struck
down in Brown & Williamson,91 which have since been codified in 21 CFR
§ 1140. The FDA has also issued draft guidance to industry detailing the
scope of the provisions contained within those regulations. 9 2
B. Statutory Structure and FDA Implementation
Historically, the FDA has struggled with the definitional frameworks
drafted by Congress; scientific and technological advancements and novel
products present particular challenges to the jurisdictional boundaries
created by the legislative definitions. This is an acute problem for FDA
regulation of e-cigarettes, as detailed below.
1. Tobacco Products
A tobacco product is defined by the TCA as
any product made or derived from tobacco that is intended for human
consumption, including any component, part, accessory of a tobacco product
(except for raw materials other than tobacco used in manufacturing a
component, part, or accessory of a tobacco product). 9 3
The statute further provides that the definition does not include an
article that is a drug, a device, or a combination product, which are subject
to the drug and medical device provisions. 94 Therefore, any product subject
to drug or device classification cannot simultaneously be a tobacco
89 Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, § 2, 123
Stat. 1776 (2009) (codified as amended in scattered sections of 5 U.S.C., 15 U.S.C., and 21
U.S.C. (2006)).
90 Id. § 3(2).
91 21 U.S.C. § 387a-1 (2006).
92 CTR. FOR TOBACCO PRODS., supra note 55.
93 21 U.S.C. § 201(rr)(1) (2006).
Id. § 201(rr)(2). The statute also states "A tobacco product shall not be marketed in
combination with any other article or product under this Act (including a drug, biologic, food,
cosmetic, medical device, or a dietary supplement)." Id. §201 (rr)(4).
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product.95 The threshold question is whether a given e-cigarette product
should be classified as a tobacco product or a drug, medical device, or drug-
device combination product.96
The definitions and requirements for drugs and medical devices hinge
specifically on the intended use of the product: is the product "intended to
affect the structure or any function of the body of man or other animals" or
"intended for use in the diagnosis, cure, mitigation, treatment, or prevention
of disease in man or other animals"? If so, it is categorized as a drug and
subject to the relevant statutory and regulatory provisions. Is the product an
"instrument, apparatus, implement, machine, contrivance, implant, in vitro
reagent" that is "intended to affect the structure or any function of the body
of man or other animals" or "intended for use in the diagnosis of disease or
other conditions, or in the cure, mitigation, treatment, or prevention of
disease, in man or other animals"? If so, it is categorized as a medical device
and subject to the relevant statutory and regulatory provisions. If a product
shares features of both, it is regulated as a drug-device combination by the
FDA.
A key feature of the definition of tobacco product is the phrase "or
derived from tobacco." 97 Clearly, cigarettes and cigars are made from
tobacco because the products themselves contain tobacco in some form
along with other ingredients. Smokeless tobacco, sold in the form of either
snuff or chewing tobacco, likewise contains tobacco as the core ingredient.9 8
Unlike traditional cigarettes and smokeless tobacco, e-cigarettes have
become popular precisely because they are promoted as having a single key
ingredient: nicotine. And nicotine is derived from tobacco. Based on a literal
reading of the statute, e-cigarettes fall within the definition of tobacco
product, despite the fact that they do not contain any tobacco.
Two other essential definitions create impediments for the FDA in the
context of e-cigarettes. A "cigarette" is defined as a tobacco product that
meets the definition of the term "cigarette" in the FCLAA and "includes
tobacco, in any form, that is functional in the product, which, because of its
95 Id. §201(rr)(2).
96 A combination product is a product having multiple mechanisms of action and is
regulated according to the "primary mode of action." 21 C.F.R. § 3.2 (2011).
97 21 U.S.C. § 201(rr)(1) (2006).
98 Smokeless Tobacco Facts, CDC, http://web.archive.org/web/20121105192631
/http://www.cdc.gov/tobacco/data-statistics/factsheets/smokeless/smokelessfacts/
index.htm (last updated Aug. 4 2011) (accessed by searching for
http://www.cdc.gov/tobacco/data-statistics/fact-sheets/smokeless/smokelessfacts/index.htm
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appearance, the type of tobacco used in the filler, or its packaging and
labeling, is likely to be offered to, or purchased by, consumers as a cigarette
or as roll-your-own tobacco." 99 The FCLAA defines a cigarette as
(A) any roll of tobacco wrapped in paper or in any substance not containing
tobacco, and (B) any roll of tobacco wrapped in any substance containing
tobacco which, because of its appearance, the type of tobacco used in the
filler, or its packaging and labeling, is likely to be offered to, or purchased
by, consumers as a cigarette described in subparagraph (A). 00
This limits cigarettes to products that actually contain tobacco. Thus,
the term electronic cigarette is a misnomer-according to the TCA, it is not
a cigarette.
Smokeless tobacco is "any product that consists of cut, ground,
powdered, or leaf tobacco and that is intended to be placed in the oral or
nasal cavity."' 0 ' Thus, although e-cigarettes are smokeless in that the
atomizer vaporizes the nicotine, they are not a smokeless tobacco product
within the meaning of the statute. These three core definitions-tobacco
product, cigarette, and smokeless tobacco-position e-cigarettes as tobacco
products as a general matter, but remove them from the realm of either
cigarettes or smokeless tobacco. This definitional positioning is significant,
as many of the core provisions of the TCA apply only to cigarettes and
smokeless tobacco.1 02
2. New and Modified Risk Products
There are also heightened requirements in the TCA for "new" and
"modified risk" products. Essentially, any product falling into either
category will require a premarket review prior to entering the market. A
"new tobacco product" is defined as any tobacco product that was not
commonly marketed in the United States as of February 15, 2007 or any
modification of a tobacco product, including a change in design or any
component, part, or constituent, where the portion modified was
commercially marketed in the United States after February 15, 2007.103 The
99 21 U.S.C. § 387(3) (2006).
15 U.S.C. § 1332(1) (2006).
101 21 U.S.C. § 387(18) (2006).
102 See generally CTR. FOR TOBACCO PRODS., supra note 55.
103 21 U.S.C. § 387j(a)(1) (2006).
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FDA has published a draft guidance that lists the types of evidence a
manufacturer can produce to establish that a product was marketed prior to
February 15, 2007, including copies of advertisements, catalog pages,
promotional material, trade publications, bills of lading, and freight bills.104
The statute also allows a showing of substantial equivalence to a product
that was commercially marketed prior to the critical date,' 05 though the FDA
has not yet provided any guidance on how this is to be accomplished by the
manufacturer. Congress borrowed the phrase and concept of substantial
equivalence from the medical device provisions. 06
A "modified risk tobacco product" is "any tobacco product that is sold
or distributed for use to reduce the harm or the risk of tobacco-related
disease associated with commercially marketed tobacco products."'O7 The
FDA has further clarified the scope of "sale or distribut[ion]" by a guidance
document providing that prohibited representations can be found on the
label,' 08 labeling,109 or any advertising, can be implicit or explicit, and can
be directed to consumers through any type of media."i0 Previously, such
products were identified with descriptors such as light, low tar, or mild. The
use of such descriptors or any representations that the tobacco product offers
a reduced risk is prohibited unless manufacturers satisfy all scientific data
and comparative study requirements set out by the FDA. "' The FDA has
actively begun to enforce these provisions.112
CTR. FOR TOBACCO PRODS., U.S. DEP'T OF HEALTH AND HUMAN SERVS.,
ESTABLISHING THAT A TOBACCO PRODUCT WAS COMMERCIALLY MARKETED IN THE UNITED
STATES AS OF FEBRUARY 15, 2007, at 3 (2011) (noting that any and all materials produced as
evidence must be dated).
105 The definition of substantial equivalence is a tobacco product that "has the same
characteristic as the predicate tobacco products" or "has different characteristics and the
information submitted contains information, including clinical data if deemed necessary by
the Secretary, that demonstrates that it is not appropriate to regulate the product under this
section because the product does not raise different questions of public health." 21 U.S.C. §
387j(a)(3) (2006).
106 Id. § 360c(i)(1)(A).
107 Id. § 387k(b)(1).
SId. § 321(1).
1
0 9 1d § 321(m).
110 CTR. FOR TOBACCO PRODS., U.S. DEP'T OF HEALTH & HUMAN SERVS., MODIFIED RISK
TOBACCO PRODUCT APPLICATIONS 6 (2012).
Ill Id. The Institute of Medicine published a special report identifying appropriate
scientific measures for modified risk tobacco products. Inst. of Med., Scientific Standards for
Studies on Modified Risk Tobacco Products (2012).
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3. Therapeutic Claims
Any claim by a manufacturer or distributor that a tobacco product has a
therapeutic effect, such as claims that a product is a smoking cessation
product or nicotine addiction treatment, will prompt regulation under the
drug and device frameworks. This requires rigorous premarket
requirements, including clinical trials, detailed product information, and
FDA review. Examples of FDA-approved drug and device smoking
cessation products include pharmaceuticals (e.g., Zyban and Chantix),
nicotine lozenges, nicotine nasal sprays, nicotine inhalers, nicotine skin
patches, and nicotine gums.113
Figure 1 depicts the relationship among these definitions in the form of
a Tobacco Product Decision Tree. As an initial matter, any representations
about the product that signal a drug or medical device intended use, or
therapeutic claims, such as use in smoking cessation, reduction, or as a
healthy alternative to smoking, will trigger the drug or medical device
provisions." 4 If no such representations exist, the next determination is
whether it is a "tobacco product." For tobacco products that entered the
market after February 15, 2007, the failure to verify substantial equivalence
triggers heightened premarket requirements." 5 Likewise, products marketed
as modified risk are subject to premarket requirements as well,"'6 including
comparison studies to existing products and submission of chemical
composition information. 117
113 For information regarding FDA approved products, see FDA 101: Smoking
Cessation Products, FDA (Dec. 2012),
http://www.fda.gov/forconsumers/consumerupdates/ucml98176.htm.
21 U.S.C. § 201(rr)(2)-(3) (2006).
115 Id. § 387j(a)(1).
16 Id. § 387k(b)(1).
117 CTR. FOR TOBACCO PRODS., supra note I 10, at 6.
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Figure 1: Tobacco Product Decision Tree
Does the manufacturer make therapentirdhealth claims about the product?
(kg., intended use for smoking cessation or smoking reduction)
Yes. Product will be
No regulated as a drug or
device
Is it a "tobaccD prodBct" under 21 U.S.C. §32 1(rr)?
Yes
Is it "new tobacco product" under 21 U.S.C §387j?
Yes, post2/15/2007.
No, pre-2/15/2007 Premarket requirements or
showing of substantial
Y equivalence applies.
Is it a "modified risk" tobacco product under 21 U.S.C §387k?
No, Basic manufacturer and distributor Yes. Premarket requiremen
registration, product labeling, reporting
requirements apply.
No. NoFDAauthority.
4. Ban on Cigarette Additives
There is an explicit ban on flavoring additives for cigarettes," a
provision chiefly targeted to curb the appeal of cigarettes to youth:
[A] cigarette or any of its component parts... shall not contain, as a
constituent... or additive, an artificial or natural flavor (other than tobacco or
menthol) or an herb or spice, including strawberry, grape, orange, clove,
cinnamon, pineapple, vanilla, coconut, licorice, cocoa, chocolate, cherry, or
coffee, that is a characterizing flavor of the tobacco product or tobacco
smoke. 1 9
350
11821 U.S.C. § 387g(a)(1)(A) (2006).
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The FDA has already carried out this ban, issuing warning letters
notifying cigarette manufacturers and distributors that any product in
violation would be subject to immediate enforcement action.120 However,
the scope of this ban and the regulations supporting it do not cover e-
cigarettes because of the scope of the definition of "cigarette" contained in
the TCA.
C. Industry-Launched Legal Challenges
Not surprisingly, the tobacco industry has lashed out against the FDA,
filing lawsuits challenging provisions of the TCA as violating the First
Amendment' 2 1 and challenging FDA enforcement actions over e-
cigarettes.' 22 Litigation had been ongoing regarding the placement of
graphic warnings on cigarette packaging and restrictions on various
promotional activities. 12 However, Attorney General Eric Holder and the
124FDA are reportedly not pursuing an appeal to the Supreme Court. FDA
officials have stated they would "undertake research to support a new
rulemaking consistent with the Tobacco Control Act." 25 As for e-cigarettes,
a 2010 decision of the D.C. Circuit in Sottera v. FDA dealt squarely with
questions about the definition of tobacco product as opposed to drug or
medical device, the scientific and technical aspects of e-cigarettes, and the
scope of intended use as it relates to therapeutic claims made by the
manufacturer.' 26 The Sottera case and its implications are discussed in detail
in Part V.
120 Consumer information, press releases, transcripts of media briefings, and warning
letters are available on the FDA's website. See Flavored Tobacco, FDA,
http://www.fda.gov/TobaccoProducts/ProtectingKidsfromTobacco/FlavoredTobacco/default.
htm (last updated Mar. 21, 2013) (last visited Apr. 5, 2013).
121 See, e.g., R.J. Reynolds Tobacco Co. v. FDA, 845 F. Supp. 2d 266 (D.D.C.), aff'd,
696 F.3d 1205 (D.C. Cir. 2012); Commonwealth Brands, Inc. v. United States, 678 F. Supp.
2d 512 (W.D. Ky. 2010).
122 Sottera, Inc. v. FDA, 627 F.3d 891 (D.C. Cir. 2010).
123 Overview: Cigarette Health Warnings, FDA,
http://www.fda.gov/TobaccoProducts/Labeling/ucm259214.htm (last updated Feb. 24, 2012).
124 Michael Felberbaum, U.S. Won't Appeal Ruling Blocking Graphic Cigarette




126 Sottera, 627 F.3d 891.
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IV. ELECTRONIC CIGARETTES Go VIRAL
The e-cigarette industry is booming-approximately 3.5 million
Americans now regularly use e-cigarettes.127 CDC studies show that e-
cigarette use quadrupled in a single year from 2009 to 2010.128 Based on
2011 numbers, 21% of adult smokers in the United States have used e-
cigarettes, 6% of all adults have tried e-cigarettes, and general awareness of
e-cigarettes rose to 60% of all adults, up from 40% in 2010.129 The co-
founder of the Tobacco Vapor Electronic Cigarette Association stated in
March 2012 that nearly 20 million e-cigarette cartridges are sold in the
United States. per week;' 30 the chief financial officer of the Association
recently estimated that the market will exceed $1 billion in U.S. sales by
December 2014.131
A. From Atomizers to Vaping: A Product Overview
Popular media and public health literature alike attribute the invention
of the e-cigarette to Hon Lik, a Chinese pharmacist, in early 2000.132 Hon
patented his invention first in the European Unionl33 and then in the United
States.134 By the mid-2000s, the e-cigarette was marketed widely in China
by the Ruyan Company and made its way to an international market by the
127 Mary Diduch, North Jersey Companies See Growth Along with E-cigarette Industry,
RECORD (Jan. 18, 2013, 7:24 AM),
http://www.northjersey.com/news/ 187414911 _NorthJersey-companies-see-growth-alongL
with e-cigarette-industry.html.
128 John Tierney, A Tool to Quit Smoking Has Some Unlikely Critics, N.Y. TIMES
(November 8, 2011), http://www.nytimes.com/2011/11/08/science/e-cigarettes-help-smokers-
quit-but-they-have-some-unlikely-critics.html.
129 About One in Five Adult Cigarette Smokers Have Tried an Electronic Cigarette,
CDC (February 28, 2013),
http://www.cdc.gov/media/releases/2013/p0228-electronic-Cigarettes.html.
130 E-Cigarettes Are Here to Stay, CONVENIENCE STORE DECISIONS (Mar. 22, 2012,
11:21 AM), http://www.csdecisions.com/2012/03/22/e-cigarettes-are-here-to-stay.
131 Diduch, supra note 127.
132 Jonathan Foulds et al., Electronic Cigarettes (E-Cigs): Views of Aficionados and
Clinical/Public Health Perspectives, 65 INT'L J. CLINICAL PRAc. 1037, 1037 (2011).
133 Improved Atomizing Electronic Cigarette, European Patent No. 2,404,515 (filed Jan.
28, 2010) (issued Jan. 11, 2012); An Aerosol Electronic Cigarette, European Patent No.
1,736,065 (filed Mar. 18, 2005) (issued June 3, 2009); Flameless Electronic Atomizing
Cigarette, European Patent No. 1,618,803 (filed Mar. 8, 2004) (issued Dec. 3, 2008).
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year 2006.135 Despite the renown of the Hon Lik invention, an examination
of patent resources reveals numerous issued patents claiming smokeless
delivery methods of nicotine, the earliest granted in 1965. 136 While these
patents share various features and functions with the Ruyan e-cigarette and
various similar products, they do not fully encompass the current mass-
marketed form of the e-cigarette. The technology rapidly developed during
the first decade of the 21st century.
The present day e-cigarette is a smokeless, battery-powered device that
vaporizes liquid nicotine for delivery via inhalation by the user. The e-
cigarette does not contain tobacco, only nicotine derived from the tobacco
plant and trace amounts of several secondary chemical ingredients. It is
composed of three parts that screw together: the nicotine cartridge; the
atomizer (which vaporizes the nicotine); and the rechargeable battery that
powers it.137 Many products are also equipped with a light-emitting diode
(LED) indicator at the end that is activated when the user draws in air. The
cartridge contains liquid nicotine and is sealed either with an aluminum foil
lid or with a plastic cork. A single cartridge can hold the nicotine equivalent
of an entire pack of traditional cigarettes.1 3 8 The composition, strengths,139
and flavoring 40 of the nicotine liquid appear highly variable across different
products.141 Sottera doing business as NJOY, identifies the ingredients
135 Joan Lowy, Ban Proposed on Electronic Cigarettes on Planes, MSNBC (Sept. 14,
2011 3:25 PM), http://www.msnbc.msn.com/id/44518729/ns/travel-news/t/ban-proposed-
electronic-cigarettes-planes.
136 Smokeless Non-Tobacco Cigarette, U.S. Patent No. 3,200,819 (filed Apr. 17, 1963)
(issued Aug. 17, 1965); see also, e.g., Electronic Smoking System, U.S. Patent No. 5,934,289
(filed Oct. 20, 1997) (issued Aug. 10, 1999); Artificial Smoke Cigarette, U.S. Patent No.
7,845,359 (filed Mar. 22, 2007) (issued Dec. 7, 2010); Aerosol Electronic Cigarette, U.S.
Patent No. 8,156,944 (filed May 15, 2007) (issued Apr. 17, 2012); Electronic Cigarette, U.S.
Patent Application No. 10/886,508, (published Jan. 27, 2005).
Legacy for Longer Healthier Lives, supra note 1.
138 See Smoking Everywhere E-Cigarette Cartridges 2.0, SMOKING EVERYWHERE,
http://www.smokingeverywhere.com/cartridges.php (last visited July 25, 2012) ("Each
cartridge is equivalent to aprox [sic] 20 traditional cigarettes (100-200 puffs).").
139 Id.
140 See Smoking Everywhere E-Cigarette Comes in Different Flavors, SMOKING
EVERYWHERE, http://www.smokingeverywhere.com/flavors.php (last visited July 25, 2012)
(advertising flavors such as apple, cherry, strawberry, and chocolate).
141 Letter from B.J. Westenberger, Deputy Dir., Div. of Pharmaceutical Analysis, FDA
to Michael Levy, Supervisor Regulatory Counsel, Office of Compliance, Div. of New Drugs
and Labeling Compliance, FDA (May 4, 2009), available at
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(though not the concentrations) on its website as: propylene glycol, nicotine,
ethanol, glycerol (glycerin), acetylpyrazine, guaiacol, myosmine, cotinine,
and vanillin.142
The atomizer, which converts the nicotine liquid into a fine mist,
consists of a metal wick and a heating element. When screwed onto the
cartridge, the nicotine liquid from the cartridge comes in contact with the
atomizer unit and is carried to the metal coil heating element. When one
draws air inwards at the end of the e-cigarette cartridge, it triggers a current
from the battery through the metal coil element in the atomizer which heats
up the nicotine liquid.
B. An Industry Profile and Marketing Tactics
The vast share of companies distributing e-cigarettes and nicotine
cartridges (also called "e-juice") market and sell their products utilizing both
the internet and in-store purchasing. Notably, e-cigarettes have begun
advertising on television, as the ban on television and radio cigarette
commercials does not apply to them.14 3 The cost of e-cigarettes range from
about $20 to $150 for the starter kits; the replacement nicotine cartridges
vary in price by retailer and location but seem to average about $12 for a 5
pack refill; and disposable e-cigarettes are now available for about $3
each. 144 While the typical e-cigarette is sold in the shape of a cigarette, many
products are sold in the shape of discreet objects such as pipes,145 pens, 146
and lipstick.14 7
Brands such as Smoking Everywhere,148 NJOY,14 9 and blu eCigs 50
142 NJOY, supra note 10.
143 "After January 1, 1971, it shall be unlawful to advertise cigarettes and little cigars on
any medium of electronic communication subject to the jurisdiction of the Federal
Communications Commission." 15 U.S.C. § 1335 (Supp. 2011).
144 These numbers were derived from online searches of e-cigarette websites, point-of
sale advertisements, and pricing at retail outlets in March 2013.
145 E-CIG E-PIPE, E-CiG.COM, http://www.e-cig.com/shopping/products/54-ecig-E-
Pipe/ (last visited Apr. 5, 2013).
146 Pen Style e-Cigarette, E-CIGS UNLIMITED, http://www.ecigsunlimited.com/kits/pen-
style-e-cigarette (last visited Apr. 5, 2013).
147 Lipstick E Cigarette, ALIBABA.COM, http://www.alibaba.com/product-
gs/501751147/Lipstick-E Cigarette.html (last visited Apr. 18, 2013).
148 SMOKING EVERYWHERE, http://www.smokingeverywhere.com (last visited June 8,
2012). The website boasts: "Smoking Everywhere Electronic Cigarette looks like a
traditional cigarette, feels like a traditional cigarette, tastes like a traditional cigarette, but it
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have a prominent market presence. The industry is dominated by small,
independent companies, with the exception of blu eCigs, which was
acquired in April 2012 by Lorilland Tobacco Company for $135 million.'
Internet-based marketing of e-cigarettes commonly utilizes affiliate
marketing schemes that enable users to distribute products and generate
profits by recruitment of customers.1 52 Some companies claim to have
policies that require those seeking affiliate status to agree not to sell e-
cigarettes to individuals under the age of 18 or to market the products as a
smoking cessation product.'53 However, e-cigarettes are available for
purchase from websites that do not verify age,' 54 raising concerns about
accessibility to minors. The strong internet presence of e-cigarettes can also
be attributed to online communities of users'55 and frequent podcasts by
sellers.' 56  The tactics are working: Google has labeled "electronic
cigarettes" as an online search term that has experienced a growth of over
5,000%. "' Search trends are becoming a focus of study for researchers. 8
Advertisements typically emphasize one or more of the following
features of their e-cigarette products: freedom to smoke anywhere; no
adverse smell, tar, smoke, or toxic chemicals; no social stigma; cost savings;
and health advantages over traditional cigarettes, with several specifically
reaching out to smokers aiming to quit or cut down. 59 Some companies and
NJOY, http://www.njoy.com (last visited Apr. 5, 2013).
150 BLU ECIGS, http://www.blucigs.com (last visited Apr. 5, 2013).
151 Diduch, supra note 127.
152 Id.153
See Cyrus K. Yamin et al., E-Cigarettes: A Rapidly Growing Internet Phenomenon,
153 ANNALS INTERNAL MED. 607, 608 (2010).
See id.
5 See, e.g., E- CIGARETTE FORUM, http://www.e-cigarette-forum.com/forum (last
visited Apr. 5, 2013) (describing itself as the "world's largest electronic cigarette website").
156 Yamin et al., supra note 153, at 607.
17 Id.
See generally John W. Ayers et al., Tracking the Rise in Popularity of Electronic
Nicotine Delivery Systems (Electronic Cigarettes) Using Search Query Surveillance, 40 AM.
J. PREVENTIVE MED. 448 (2011); Annice E. Kim et al., Smokers' Beliefs and Attitudes About
Purchasing Cigarettes on the Internet, 121 PUB. HEALTH REP. 594 (2006); Annette K. Regan
et al., Electronic Nicotine Delivery Systems: Adult Use and Awareness of the "E-Cigarette"
in the USA, 22 Tobacco Control 19 (2013).
159 The University Medical and Dental School of New Jersey (UMDNJ) has amassed an
impressive collection of cigarette and tobacco advertising and marketing. UMDNJ, TRINKETS
AND TRASH: ARTIFACTS OF THE TOBACCO EPIDEMIC, http://www.trinketsandtrash.org. Visitors
to the website can search by category; selecting "e-cigarettes" will generate 40 results of e-
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distributors advertise their products as not emitting secondhand smoke and
as ecologically friendly.160 The accuracy of these claims is unclear and hotly
contested.161 Premium Electronic Cigarette, which claims to be "one of the
largest retailers of electronic cigarette systems and kits" states on its website
that "[o]ne of the most important reasons why smokers are switching to
electronic cigarettes is because they allow users to determine their nicotine
intake, which is a great way to reduce their smoking habit without resorting
to either quitting abruptly or to nicotine patches and gum." 62 American Blue
Tip products are advertised as "a healthier, convenient alternative to
cigarettes" and "so effective as a substitute for cigarettes."' 6 3 It also directs
consumers to "feed the hand to mouth habit."' 64 In an ironic, almost
inspiring twist, actor Stephen Dorff (for blu) tells consumers to "[r]ise from
the ashes."'16
Many celebrities have also touted the smoking cessation use of e-
cigarettes publicly.166 For example, in a 2010 interview with David
Letterman, Katherine Heigl raved about her e-cigarette, stating that she had
tried everything-the nicotine patch, gum, and prescription medication
before turning to the e-cigarette.167 She stressed to Letterman that her goal
cigarette advertising from the past three years. These features of product claims were
identified by the author using those 40 advertisements, television commercials, and direct
email advertisements.
160 Yamin et al., supra note 153, at 607.
161 Id.
162 PREMIUM VAPES, http://www.premiumecigarette.com (last visited Apr. 5, 2013).
163 See Sch. of Pub. Health, Trinkets and Trash: Artifacts of the Tobacco Epidemic,
UNIV. OF MED. & DENTISTRY OF N.J.,
http://www.trinketsandtrash.org/detail.php?artifactid=7002 (last visited Apr. 5, 2013).
164 Id.
165 See Sch. of Pub. Health, Trinkets and Trash: Artifacts of the Tobacco Epidemic,
UNIV. OF MED. & DENTISTRY OF N.J.,
http://www.trinketsandtrash.org/detail.php?artifactid=7410 (last visited Apr. 5, 2013).
166 See, e.g., Celebrities Smoking Electronic Cigarettes: Leo DiCaprio, Katherine Heigl,
JWoww Puff Away, HUFFINGTON POST (May 8, 2012, 4:46 PM),
http://www.huffingtonpost.com/2012/05/08/celebrities-smoking-electronic-cigarettes-
photos.n_1500814.html.
167 CanadaVapes, Katherine Heigl & David Letterman Vape Electronic Cigarettes,
YouTUBE (Sept. 29, 2010) http://www.youtube.com/watch?v-ysGyfLwwrls. One excerpt is
particularly interesting:
Katherine: "So I started to quit .... I tried everything; I did the patch, I did the
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was that she would eventually wean herself off of the e-cigarette entirely
after utilizing it to quit smoking.16 8 Charlie Sheen was named the face of a
new e-cigarette called the NicoSheen in 2011.169 OK! Magazine recently
discussed Catherine Zeta-Jones being gifted Smokestik electronic cigarettes
by a company representative to "support her quitting the bad habit."7 o A
recently publicized celebrity endorsement for e-cigarettes came from Elliott
Storm, a high profile disabled Vietnam veteran and author. '7
Despite industry exhortations that e-cigarettes are not intended to be
used in smoking cessation, public impressions reflect a majority of users
who either rely on e-cigarettes to quit or reduce smoking, or who believe
that e-cigarettes are a safer alternative to traditional cigarettes. Survey
research indicates efforts to quit smoking were the most frequently cited
reason for use of e-cigarettes.17 2 The draw of the e-cigarette for smokers is
that it delivers nicotine to counter nicotine withdrawal symptoms, it evokes
the psychological response to cigarette smoking because of its shape, and it
supports the familiar behavioral aspects of smoking.' 73 The behavioral and
physical stimuli alone (such as that associated with merely holding an unlit
cigarette) are capable of reducing the craving to smoke. 174
A number of studies have investigated public and user perceptions
about e-cigarettes.' 75 In a 2011 survey of 104 e-cigarette users, "[t]hree
David: "and then you wean yourself off eventually and you'll be just fine."
Katherine: "Yeah that's the idea."
168 Id.
169 Charlie Sheen Unveiled as the Face of New Electronic Cigarette, DAILY MAIL (Apr.
30, 2011, 5:47 PM), http://www.dailymail.co.uk/tvshowbiz/article-1382270/Charlie-Sheen-
unveiled-face-new-electronic-cigarette.html.
170 Laura Lane, Catherine Zeta-Jones Trying to Quit Smoking, OK! MAGAZINE, (Aug. 5,
2011, 7:28 PM), http://www.okmagazine.com/news/catherine-zeta-jones-trying-quit-
smoking.
PRWeb, 21 Century Smoking Electronic Cigarette Company Gets Celebrity
Endorsement, NEWSON6.coM, (July 2, 2012 10:07 AM),
http://www.newson6.com/story/18931593/21-century-smoking-electronic-cigarette-
company-gets-celebrity-endorsement.
172 Yamin et al., supra note 153, at 607 (citing a study showing that 65% of respondents
indicated that use of e-cigarettes was to quit smoking).
173 Michael B. Siegel et al., Electronic Cigarettes as a Smoking-Cessation Tool: Results
from an Online Study, 40 AM. J. PREVENTIVE MED. 472, 474 (2011).
174 Id. at 472.
175 See, e.g., Ayers et al., supra note 158; Jean-Frangois Etter, Electronic Cigarettes: A
Survey of Users, 10 BMC PUB. HEALTH 231 (2010); Foulds et al., supra note 132; Regan et
al., supra note 158.
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quarters started using e-cigs with the intention of quitting smoking and
almost all felt that the e-cig had helped them to succeed in quitting
smoking."' 6 One study reports that among 3,037 users of e-cigarettes, 77%
of respondents said that they used them to quit smoking or to avoid relapse
and 20% said that they used them to reduce consumption of tobacco with no
intent to quit smoking. 177 In a larger survey involving 3,587 participants,
over three quarters of respondents likewise stated
that one reason for their use of e-cigarettes was to quit smoking or avoid
relapse. 178
C. Public Perceptions, Public Health Perspectives, and a Dearth of
Scientific Data
Several core concerns about e-cigarettes have been identified. The first
concern is the uncertainty: the FDA and public health advocates seek
conclusive studies as to the actual constituents of the products on the market
in terms of nicotine levels, toxins, and other chemicals.179 The FDA has
directed extensive coverage to the risks of e-cigarettes, providing consumers
with information on its website.' 80 The second concern is the particular risk
to youth: product flavorings such as grape, vanilla, and chocolate are being
flagged as chiefly appealing to youth, encouraging them to use flavored e-
cigarettes because popular flavorings in traditional cigarettes have now been
banned.' 8 ' The third concern is the misconception about the health benefits
of e-cigarettes: claims made by manufacturers and distributors related to
utility in smoking cessation or reduction in cigarette use, and statements
176 Foulds et al., supra note 132.
177 Id. at 1040-41.
178 Jean-Frangois Etter & Chris Bullen, Electronic Cigarette: Users Profile, Utilization,
Satisfaction and Perceived Efficacy, 106 ADDICTION 2017 (2011).
179 See, e.g., Bridget M. Kuehn, FDA: Electronic Cigarettes May Be Risky, 302 J. AM.
MED. Ass'N 937, 937 (2009); see also Kuschner et al., supra note 22; Sungkyu Lee et al.,
Public Health Challenges of Electronic Cigarettes in South Korea, 44 J. PREVENTIVE MED. &
PUB. HEALTH 235 (2011); Anna Trtchounian et al., Conventional and Electronic Cigarettes
(E-Cigarettes) Have Different Smoking Characteristics, 12 NICOTINE & TOBACCO RESEARCH
905 (2010); Constantine I. Vardavas et al., Short-Term Pulmonary Effects of Using an
Electronic Cigarette: Impact on Respiratory Flow Resistance, Impedance, and Exhaled
Nitric Acid, 141 CHEST 1400 (2012).
180 Electronic Cigarettes (e-Cigarettes), FDA, http://www.fda.gov/newsevents/
publichealthfocus/ucml72906.htm (last updated Oct. 9, 2012).
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about the healthfulness of e-cigarettes are under close scrutiny.182 The fourth
concern is the risk of overconsumption: there is some attention directed to
the lack of finality to an e-cigarette as being a potential problem, as smokers
who have turned to the e-cigarette no longer have the butt of the cigarette as
a cue to stop smoking. Unlike a traditional single cigarette that is typically
smoked in its entirety and then discarded, use of an e-cigarette can be
extendedl 83 in that a nicotine cartridge can contain up to twenty times the
amount of nicotine of a single cigarette.' 84 While a cigarette smoker has the
ability to keep track of how many cigarettes in a pack he or she consumes, a
nicotine cartridge has no such measure.
Little is known about the safety or adverse effects of e-cigarettes.'8 '
The popular medical information website, WebMD, recognizes the
widespread use of e-cigarettes for smoking cessation purposes and urges
clinical trials to determine safety.' 86 Scientific and clinical publications have
only begun to target issues related to e-cigarette use. An FDA study of two
e-cigarette products revealed tobacco-associated chemicals, trace amounts of
toxic chemicals, and varying levels of nicotine present in identically-labeled
products.'87 Only one existing product, the Ruyan e-cigarette, has undergone
182 See, e.g., Zachary Cahn & Michael Siegel, Electronic Cigarettes as a Harm
Reduction Strategy for Tobacco Control: A Step Forward or a Repeat of Past Mistakes?, 32
J. PUB. HEALTH POL'Y 16 (2011); Pasquale Caponnetto et al., Successful Smoking Cessation
with Electronic Cigarettes in Smokers with a Documented History of Recurring Relapses: A
Case Series, 5 J. MED. CASE REP. 585 (2011); Riccardo Polosa et al., Effect of An Electronic
Nicotine Delivery Device (E-Cigarette) on Smoking Reduction and Cessation: A Prospective
6-Month Pilot Study, II BMC PUB. HEALTH 786 (2011); Siegel et al., supra note 173. In fact,
the California Attorney General filed suit against Smoking Everywhere in early 2010 for
misleading claims. Office of the Attorney Gen., Brown Sues Electronic Cigarette Maker for
Targeting Minors and Misleading Advertising Claims, CAL. DEP'T JUSTICE (Jan. 13, 2010),
http://oag.ca.gov/news/press-releases/brown-sues-electronic-cigarette-maker-targeting-
minors-and-misleading.
183 Respondents of one survey of e-cigarette users indicated an estimated median of
twenty uses per day (where a single use was defined as 10-20 puffs). Foulds et al., supra note
132, at 1039.
184 Electronic Cigarette Frequently Asked Questions (FAQ's), EPUFFER,
http://www.epuffer. com/eshop/faqs-frequently-asked-questions.html (last visited Apr. 5,
2013). The website provides that "[o]ne regular cigarette would be equivalent to 10-15
epuffs," with the "Elite Classic" ePuff cartridge containing the nicotine of 18-20 cigarettes
and the "Eaze [sic] Magnum" ePuff cartridge containing the nicotine of 20-25 cigarettes.
185 Siegel et al., supra note 173, at 472.
186 Daniel J. DeNoon, Survey: E-Cigarettes May Help Smokers Quit, WEBMD (Feb. 8,
2011), http://www.webmd.com/smoking-cessation/news/20110208/survey-e-cigarettes-may-
help-smokers-quit.
187 Kuehn, supra note 179.
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a rigorous scientific study regarding safety using a risk-benefit
methodology, though Ruyan funded the study.188
General questions about the overall safety of the products are being
posited in light of several reports of death or serious injury resulting from e-
cigarettes. In the United States, there have been at least two reports of e-
cigarettes exploding in users' faces and hands causing severe injuries
including blown out teeth, extensive bums and tissue damage to lips and
tongue, bums to the hands, and hearing and vision loss.' 8 9 Furthermore, a
British doctor attributed the death of a patient from severe lipoid
pneumonia, a lung disease, to e-cigarette use.i90 He posited (and continues
to assert) that the inhalation of the oil in the e-cigarettes caused a similar
result to those who are overexposed to oil inhalation over the course of their
lifetime.19'
V. FDA ACTION AND JUDICIAL REVIEW IN SOTTERA V. FDA
The FDA has begun testing the bounds of the statutory framework for
regulation of tobacco products through enforcement actions against e-
cigarette products. Although ultimately an unsuccessful attempt by the FDA
to regulate e-cigarettes as drug-device products, the Sottera case is
instructive in beginning to delineate the operative regulatory framework for
the FDA as it faces a proliferating e-cigarette market.
A. Product Detention and Preliminary Injunction
The FDA has asserted its jurisdiction over e-cigarettes in two instances.
In September 2008, the FDA detained several import shipments of e-
Murray Laugesen, Second Safety Report on the Ruyan E-Cigarette, HEALTH NEW
ZEALAND LTD, (Apr. 9, 2008), http://www.mlm-
infos.com/files/2ndsafetyreport_9apr08_930.pdf.
189 Mikaela Conley, Man Suffers Severe Injuries After E-Cigarette Explodes in His
Mouth, ABC NEWS (Feb. 15, 2012), http://abcnews.go.com/Healthlelectric-cigarette-
explodes-fla-mans-face/story?id=15645605; Electronic Cigarette Explodes in Muskogee
Woman's Hand, Fox23.coM (Apr. 18, 2012, 8:35 PM),
http://www.fox23.com/mostpopular/story/Electronic-cigarette-explodes-in-Muskogee-
womans/ek2x6P6rvkyLu5cMrvGwVQ.cspx; Update: Was Exploding E-Cigarette a "Mod"?,
CSP DAILY NEWS (Feb. 20, 2012), http://www.cspnet.comnews/tobacco/articles/update-was-
exploding-e-cigarette-mod.
190 Gateshead Doctor Calls for Research into "E-Cigarettes," BBC NEWS (Mar. 28,
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cigarettes manufactured by Smoking Everywhere, Inc. and subsequently
issued notices of detention for violation of the FDCA.192 A December 2008
correspondence establishes the asserted basis of jurisdiction: e-cigarettes
and component parts are "intended to affect the structure or function of the
body, and to prevent, mitigate, or treat the withdrawal symptoms of nicotine
addiction,"' 9 3 thereby subjecting them to pre-market requirements under the
FDCA as drug-device products. In March 2009, the FDA issued a refusal of
admission notice and directed the detained products be exported or
destroyed within 90 days.194 In April 2009, the FDA also detained Sottera's
shipment of e-cigarettes.195 Smoking Everywhere and Sottera filed
complaints on April 28, 2009 and May 15, 2009, respectively, seeking to
enjoin the FDA from regulating e-cigarettes as drug-device combinations
under the FDCA. The district court determined that the balance of harms
favored Sottera and Smoking Everywhere and issued a preliminary
injunction against the FDA.1 6
After detaining the imports, the FDA analyzed samples of the two
products, including nicotine cartridges of various proclaimed amounts.
Although the analysis was not a basis for the original detention of the
products and not at issue in the case, the FDA has used the findings to
support its position that e-cigarettes pose serious health risks. A May 2009
memorandum generated by the Deputy Director of the Division of
Pharmaceutical Analysis within the Center for Drug Evaluation and
Research at the FDA reported harmful volatile components in tests of both
products, including tobacco-specific nitrosoamines and impurities, and even
traces of diethylene glycol, a poisonous organic compound.197 The tests also
found that identically labeled cartridges contained varying amounts of
nicotine.
B. Appellate Review
On appeal to the D.C. Circuit, the court addressed whether the NJOY e-
192 Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 64 (D.D.C.), affd sub nom.
Sottera, Inc. v. FDA, 627 F.3d 891 (D.C. Cir. 2010).
193 Id. at 65.
194 Id.
195 Id.
196 Id. at 78-79. Smoking Everywhere did not continue as a party on appeal.
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cigarette, marketed by Sottera, could be regulated as a drug or medical
device or merely as a tobacco product.1 99 Affirming the judgment of the
lower court to grant a preliminary injunction against the FDA, the D.C.
Circuit also held that the FDA's authority over the NJOY e-cigarette was
limited to the provisions covering tobacco products.2 00 Though the court
noted a weak factual record on the marketing of e-cigarettes,201 it found that
without evidence that the company was making therapeutic claims, the
"definitional line laid down in Brown & Williamson . . . leaves the FDA
without jurisdiction over these products under the FDCA's drug/device
provisions."2 02
The NJOY product itself was labeled for smoking pleasure rather than
as a therapeutic or smoking cessation product,203 which was critical to the
court's decision. In reaching its conclusion, the majority read Brown &
Williamson to exclude all tobacco products from the drug and device
provisions (not just those products on the market at the time of the holding,
i.e., cigarettes and smokeless tobacco) as long as the manufacturer, NJOY,
did not make drug-like claims. 204 The court determined that Congress had
consciously developed a broader statutory scheme that distinguished
customarily marketed tobacco products, including more than just cigarettes
and chewing tobacco, from those tobacco products marketed for therapeutic
205purposes.
C. Forgoing Further Appeal
The FDA ultimately decided to forgo appeal and issued a letter to the
public setting forth its reasoning.206 The letter assured adherence to the
jurisdictional lines drawn by the Sottera court, while also indicating the
relevance of other provisions of the statute that are implicated by e-
199 Sottera, Inc. v. FDA, 627 F.3d 891 (D.C. Cir. 2010).
200 Id. at 897. This authority includes restrictions on sale, advertising, manufacture, and
the establishment of standards. Id. at 898.
201 Id. at 898.
202 Id.
203 Id. at 893.
204 Id.
205 Id. at 897.
206 Letter from Lawrence R. Deyton, Dir., Ctr. for Tobacco Products & Janet
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cigarettes.20 7 For example, the FDA included requirements covering new
tobacco products and a portion of the definition of tobacco product that
includes those tobacco products marketed in combination with other FDA-
regulated products. 20 8 The letter also emphasized that the FDA may issue a
guidance document regarding therapeutic claims and triggers for regulation
as a drug or medical device.209
The decision in Sottera and the FDA's subsequent decision not to
appeal are woefully unsatisfying. The remainder of this Article is premised
on two complementary positions. The first is that the TCA is inadequate for
oversight of e-cigarettes, which are novel nicotine delivery devices for
which the FDA ought to have the authority to assess safety and efficacy. E-
cigarettes are not typical cigarettes consisting of tobacco grounds rolled in
paper. Compared to a traditional tobacco product, e-cigarettes deliver a
purer form of nicotine without the tobacco, the intake of nicotine is more
rapid, and the user does not have the behavioral cue of a cigarette butt to
signal the completion of a normal dose. Surely, the FDA safety assessment
in the context of new drugs and devices deals with this phenomenon exactly,
where novel delivery of excessive levels of active ingredients produce
uncertain effects on the body.
The second position responds to the FDA's announcement that it will
regulate e-cigarettes under the framework created by the TCA rather than
pursue jurisdiction under the drug and medical device provisions. Going
forward, the FDA will need to assess the industry as a whole to identify
those claims, representations, and uses that do in fact trigger the drug-
medical device requirements. This will require a prime focus not only on the
explicit claims and representations of intended use of the product by both
the original manufacturer and distributors, but also on implicit
representations and actual consumer use.
VI. GOING FORWARD: STRENGTHENING REGULATION OF ELECTRONIC
CIGARETTES
Absent a change in position from the FDA, e-cigarettes will be
regulated under the framework espoused in Sottera. This Part informs the
process of deciphering whether a manufacturer or distributor is making






Yale Journal of Health Policy, Law, and Ethics, Vol. 13 [2013], Iss. 2, Art. 2
https://digitalcommons.law.yale.edu/yjhple/vol13/iss2/2
YALE JOURNAL OF HEALTH POLICY, LAW, AND ETHICS
use as a drug-device product. Despite the problematic analysis presented by
the court in Sottera, particular claims, representations, and actual consumer
use of e-cigarette products for smoking cessation or reduction do in fact
trigger drug-medical device provisions. Even if the FDA takes the stance
that actual consumer use fails to trigger drug-device provisions, various
product features may trigger heightened requirements for new tobacco
products and modified-risk tobacco products. The FDA may also rely on
broad statutory authority from Congress to promulgate product-specific
regulations and guidance.
A. Triggering Drug-Device Regulation Through Marketing, Promotion, and
Consumer Use
Where the manufacturer of a tobacco product makes any claims or
statements about the intended use of the product that fall within the drug or
medical device definition, those statutory and regulatory provisions will
apply. The FDA has clarified the scope of intended use by regulation:
The intent is determined by such persons' expressions or may be shown by
the circumstances surrounding the distribution of the article. This objective
intent may, for example, be shown by labeling claims, advertising matter, or
oral or written statements by such persons or their representatives. It may be
shown by the circumstances that the article is, with the knowledge of such
persons or their representatives, offered and used for a purpose for which it
is neither labeled nor advertised.210
This regulation makes clear that intended use extends beyond explicit
claims and representations by the original manufacturer and the subsequent
marketer. In fact, intended use includes representations by those affiliated
with the product and actual consumers, if the distributor has knowledge of
actual consumer use.
Claims made by the manufacturer on the product label and in marketing
and promotion are the primary indicators of intended use. The FDA and
Federal Trade Commission have made clear that company and manufacturer
websites are also a source of promotional claims for purposes of
enforcement. Increased monitoring and surveillance of manufacturer and
distributor claims on labels and in advertising and promotion by the FDA
and the CTP would assist in identifying problematic claims.
364
210 21 C.F.R. § 201.128 (2011).
XIll:2 (2013)
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The FDA confronts challenges in several product realms by definitional
lines demarcated by intended use. 2 11 For example, a cosmetic 212 is also
regulated as a drug if claims are made that the product affects the structure
or function of the human body or that the product will improve health or
treat a health or disease-related condition.2 13 The FDA has struggled with
this line between a drug and a cosmetic for decades, as reflected by a litany
of warning letters to industry2 14 as well as informational materials on its
website.215 Even absent manufacturer claims, a cosmetic with a drug or
drug-like intended use gleaned through customary consumer use or
consumer perception may be regulated as a drug.216 Unlike cosmetics, e-
cigarette claims will not involve structure-function aspects, such as "lifting"
wrinkles, "rebuilding" cells, or "repairing" imperfections.
With e-cigarettes, the challenge will likewise be policing the
definitional lines. If a tobacco product manufacturer or distributor makes
drug or medical device claims, it will be subject to the related requirements.
For tobacco products, the traditional cigarette and smokeless tobacco
manufacturers are careful to avoid marketing claims that sound therapeutic
in nature, such as cessation or addiction treatment (triggering the drug
requirements) or risk reduction (triggering the modified-risk requirements).
The FDA will need to discern what claims made by e-cigarette
manufacturers will similarly trigger heightened requirements. Given the
novelty of e-cigarette technology (which means that the FDA is facing a
rapid leaming curve), coupled with aggressive marketing campaigns
requiring vigilant watchdogging on the part of an already stressed
administrative agency, manufacturers and distributors of e-cigarettes are
currently thriving because of statutory and regulatory gaps and the
211 See Jordan Paradise & Ethan Fitzpatrick, Synthetic Biology: Does Re-Writing
Nature Require Re-Writing Regulation?, 117 PENN ST. L. REv. 53 (2012).
212 A cosmetic is another definition in the FDCA hinging on intended use, defined as
"intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise
applied to the human body or any part thereof for cleansing, beautifying, promoting
attractiveness, or altering the appearance ..... 21 U.S.C. § 321(i) (Supp. 2011).
213 See id. § 321(g)(1)(C). Foods and dietary supplements can make structure-function
claims as long as they do not venture into unallowable health or disease-prevention claims.
214 Warning Letters Address Drug Claims Made for Products Marketed as Cosmetics,
FDA, http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatorylnformation/
ComplianceEnforcement/WarningLetters/ucm081086.htm (last updated Nov. 26, 2012).
215 Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?), FDA (July 8, 2002, updated Apr.
30, 2012),http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatorylnformation/
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inadequate enforcement. It will be years before the FDA can catch up with
the claims targeted to consumers, though recent statements from the FDA
indicate that this is a priority area following the outcome of Sottera.21 Aside
from direct representations made in marketing and promotion, any
representation from the manufacturer or distributor in any public forum
technically constitutes providing evidence of intent. Communications and
reports to other administrative agencies within the federal government are
readily available to the FDA to glean an intended use from representations
contained within those sources. The FDA and other regulatory agencies
often rely on these representations to support enforcement actions. For
example, in framing a 1987 Regulatory Letter, the Department of Health and
Human Services (DHHS) relied on the statements that Advanced Tobacco
Products, Inc. made in labeling and promotional literature and in reports to
the Securities and Exchange Commission (SEC) to support the finding that
the FAVOR smokeless cigarette product2 18 was a nicotine delivery
system.219 Accordingly, the letter stated that as a nicotine delivery system
intended to affect the structure or function of the body through
pharmacologic action, the FAVOR cigarette had violated the new drug
provisions under the FDCA and its marketing should be discontinued.22 0
The letter heavily referenced statements made by the company in its annual
report to the SEC, including references to medical literature regarding the
effects of nicotine on the nervous system and its addictive qualities. 2 2 1 The
company responded with a letter indicating that distribution of the product
had been curtailed pending preparation of a detailed response,22 2 and the
company ultimately removed the product from the market voluntarily
without enforcement action by the DHHS. Given the voluntary withdrawal
217 Letter from Lawrence R. Deyton, supra note 206.
218 Conceptually similar to present day e-cigarettes, when air is drawn through the tube
over the nicotine solution, a small amount of nicotine is inhaled by the user. However, it
contains no heating element or battery and operates simply by drawing air over the nicotine
solution. U.S Patent No. 4,284,089 col. 3 11. 25-30, (filed Apr. 2, 1980). The specific amount
of nicotine inhaled during each draw of air is dictated by how constricted the passageway
through the nicotine chamber is and by alteration of the surface area of the absorbent
material. Id. col. 5 11. 10-20.
219 Regulatory Letter from Daniel L. Michels, Dir., DHHS, Office of Compliance, Ctr.
for Drugs & Biologics (Feb. 9, 1987),
http://www.legacy.library.ucsf.edu/documentStore/hle/b/ heb65e00/Sheb65e00.pdf.
220 Id. at 2.
221 Id. at 1.
222 Letter from James E. Turner, Chief Operating Officer, Advanced Tobacco Products,
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of the product, reliance on these representations has not been tested in the
courts.223
Patent filings with the U.S. Patent and Trademark Office or other
international patent bodies are another useful resource. Any information
provided to support a patent application and subsequent patent is made
public and becomes part of the public domain, accessible to anyone via the
internet. As a means to satisfy utility and novelty requirements in patent
law, inventors support their invention description with reasons that their
invention is useful and new for a particular application. 2 24 Patents for e-
cigarettes may house a wealth of statements relevant to whether the
manufacturer is representing the product as a smoking cessation or reduction
product or is making claims of therapeutic benefit as compared to smoking
risks.
For example, the inventor of the FAVOR smokeless cigarette described
above was granted a patent in 1981 for a smokeless cigarette consisting of
"a container defining a passageway therethrough and having a mouthpiece;
means containing a source of vaporizable nicotine in fluid communication. .
[and] means for preventing the evaporation of said nicotine during periods
of non-use . . . .,,225 The invention was "designed to reduce or eliminate the
disadvantages associated with conventional smoking habits using
combustible cigarettes" 226 and to "eliminate or ameliorate the adverse
consequences" of smoking. 227
The Lik Hon patent (assigned to Best Partners Worldwide Limited,
reportedly acquired by Ruyan Investments) makes representations such as:
223 In the litigation leading up to Sottera, the FDA argued that the assertion of
jurisdiction over the FAVOR smokeless cigarette is relevant for purposes of e-cigarette
regulation. The district court noted that such an action was not judicially reviewed, it
predated the Supreme Court's decision in Brown & Williamson, and it was "not in step with
the reasoning of that case." Smoking Everywhere, Inc. v. FDA, 680 F. Supp. 2d 62, 72
(D.D.C.), affd sub nom. Sottera, Inc. v. FDA, 627 F.3d 891 (D.C. Cir. 2010). However, the
treatment of the FDA's assertion of jurisdiction over the FAVOR product is not satisfactorily
discussed in the lower court decision, is relegated to a footnote, and is premised on a
seemingly inaccurate framing of the reasoning of Brown & Williamson. Specifically, the
district court states that the reasoning in Brown & Williamson was "based in part on FDA's
representations to Congress that customarily-marketed tobacco products are not subject to
FDA jurisdiction absent therapeutic claims." Id. Notably, the case does not address other
aspects of the FAVOR history, namely the FDA's reliance on the SEC filings, to construe
intended use of the product.
224 See 35 U.S.C. §§ 101-102 (2006).
225 U.S. Patent No. 4,284,089, supra note 217, at col. 14 11. 52-59.
226 Id. at col. I 11. 9-11.
227 Id. at col. 2 11. 4-5.
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"only contain[ing] nicotine without the harmful tar;" 2 28 "provide[s] an
electronic atomization cigarette that may function as a substitute for
smoking cessation products or as a cigarette substitute;" 2 29 and "[the]
advantages of the present invention include smoking without tar,
significantly reducing the cancerogenic risk."2 30 The patent also generally
points out that "some cigarette substitutes" such as "nicotine patch, nicotine
mouthwash, . . . nicotine chewing gum, nicotine drink" have a "major
disadvantage" 231 and that the invention "overcome[s] the above-referenced
drawbacks."23 2 A Li Han patent (assigned to Ruyan Investments) provides
that the invention "has been designed to provide an aerosol electronic
cigarette that substitutes for cigarettes and helps the smokers to quit
smoking." 2 33 The representations present within each of these patents
strongly support a finding of an intended therapeutic use as a cessation or at
least a modified risk product. However, it is unclear whether the FDA will
succeed in using a patent claim as evidence of intended use for a particular
e-cigarette product given complicated licensing arrangements that may exist
between the inventor, patent assignee, and industry.
In tandem with increased general monitoring of marketing and
promotion to mine for product claims, the FDA could search SEC filings
and product-related patents in connection with manufacturer and distributor
registration. The FDA could require submission of such materials at the time
of registration, and on an annual basis through regulation or a guidance
document.
B. Application ofNew and Modified Risk Provisions
Even where no drug or medical device claims are present, the FDA has
at its disposal regulatory authority over the categories of new tobacco
products and modified-risk products. Reports detailing the history of e-
cigarettes identify a general presence in the U.S. market in the mid-2000s,
with many sources pinpointing the exact date as some time in 2007. The
FDA ought to determine when the various e-cigarette products entered the
U.S. market and whether and to what extent changes in design are amenable
to being grandfathered in as substantially equivalent to products already on
228 U.S. Patent No. 7,832,410, at [57] (filed Mar. 18, 2005).
229 Id. at col. 1 11. 53-55.
230 Id. at col. 2 11. 62-64.
231 Id. at col. I II. 35-41 (internal quotation marks omitted).
232 Id. at col. I 11. 52.
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the market. The guidance to industry regarding new tobacco products is
scant except to provide sources of evidence of market presence prior to the
critical date.234 Thus, elaboration on the role of substantial equivalence
ought to be a priority for the FDA.
Future direction from the FDA on the new tobacco provisions will be
important as the agency examines e-cigarettes and the timing of market
entry for the various products and their progeny. The TCA appears to give
the FDA the requisite authority to interpret the definition of substantial
equivalence as applied to tobacco products. The FDA should consider
interpreting the term strictly, not allowing incremental product changes
without pre-market assessment. In the realm of devices, the FDA's
inconsistent interpretation of substantial equivalence has raised significant
safety concerns despite strong countervailing policy goals such as
encouraging innovation and rapid introduction of new products.23 Setting
clear guidance is imperative.
Perhaps more useful for regulation and enforcement against e-cigarettes
are the modified-risk products provisions contained in the TCA. Those
products sold or distributed as reducing the harm or risk of disease
associated with traditional cigarettes are subject to heightened requirements
prior to marketing, including scientific data and comparative studies. 236 The
FDA can use statements about risk reduction made in marketing,
promotional materials, and SEC and patent filings to support regulation of e-
cigarettes as modified risk tobacco products. Any label, marketing and
promotional material, website, or other manufacturer representations about
the product will likewise support heightened requirements. As noted in Part
III, the FDA is also in the process of implementing these provisions of the
TCA; guidance should focus on specific e-cigarette claims triggering
heightened requirements.
C. E-Cigarette-Specific Regulations and Guidance for Standardization,
Reporting, and Labeling
Alongside scrutiny of product claims, actual consumer use, and
application of the new and modified-risk provisions, the FDA should also
begin to gather information and impose standards on the e-cigarette
industry. Additional efforts to regulate e-cigarettes should be directed
234 See Ctr. for Tobacco Prods., supra note 104.
235 See Paradise, supra note 60, at 488.
236 See 21 U.S.C. § 387k(b)(1) (2006); CTR. FOR TOBACCO PRODS., supra note I10.
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toward the development of requirements to force uniformity and
standardization across the industry, provide consumers with information
regarding ingredients and nicotine levels, and create quality control
mechanisms and product standards. This is not as daunting a task as it may
seem.
The broad authority granted to the FDA, coupled with detailed statutory
provisions, provides groundwork for the development of regulations and
guidance regarding e-cigarette manufacturing and sale. Most relevant are
provisions mandating manufacturer registration, 237 disclosure to the FDA of
ingredients, 23 8 and manufacturing practice requirements.2 39 The statute
requires every owner or operator engaged in the manufacture, preparation,
and processing of tobacco products to register the name, place of business,
and a list of all tobacco products. 24 0 The statute also requires the FDA to
promulgate regulations requiring testing and reporting of ingredients,
constituents, and additives by brand and sub-brand requisite to protect the
public health.2 41 All ingredients, including tobacco substances, compounds,
and additives, as well as a description of the milligram content, delivery, and
form of nicotine in each tobacco product, must be reported.24 2 Harmful and
potentially harmful constituents (HPHCs) in tobacco products must be
reported by brand and quantity; 2 43 the FDA has already developed a list of
93 HPHCs. 244 At a minimum, the FDA may require e-cigarette
manufacturers and distributors to register and file a list of all tobacco
products, ingredients, and HPHCs. 24 5
The FDA has issued several nonbinding guidance documents for
industry explaining the agency's current plans to interpret and develop the
statutory requirements for filing and reporting.2 46 The agency provides that
as it moves forward with full implementation and enforcement of the
237 21 U.S.C. § 387e (2006).
238 Id. § 387d.
239 Id. § 387e(e).
240 Id. § 387e.
241 Id. § 3870(a).
242 Id. § 387d.
243 Id. § 387d(a)(3).
244 Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco
Smoke: Established List, FDA (Mar. 2012), http://www.fda.gov/TobaccoProducts/
GuidanceComplianceRegulatoryInformation/ucm297786.htm.
245 See REGISTRATION AND PRODUCT LISTING, supra note 88.
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reporting requirements via rulemaking it will revise or withdraw the
guidelines accordingly.247 While these guidance documents signal
movement from the FDA, priority should be given to spell out these
requirements to the e-cigarette industry and make it clear that the filing and
reporting requirements apply to them.
Aside from the these actions covering filing and reporting, the FDA
should require mandatory listing of all e-cigarette ingredients for labeling
and packaging, similar to nutrition facts for foods2 48 and supplement facts
for dietary supplements. 24 9 The ingredients should be listed on each starter
kit, nicotine cartridge, and disposable product in addition to all
accompanying labeling and packaging for the product. The format and
requirements for this information should issue through notice and comment
rulemaking.
The TCA also grants the FDA authority to establish product
standards.250 Uniformity and standardization are also vital for the entire e-
cigarette industry to assure consumer comprehension and industry
accountability. This includes clearly conveyed nicotine levels for initial and
refill nicotine cartridges; FDA-cleared design, mechanisms, and parts for the
atomizer, battery, and nicotine cartridge; and, ideally, some notification to
the user of the amount of nicotine consumed. This could possibly be built
into the LED system as a changing color notification as more nicotine is
consumed.
Quality control mechanisms are also necessary as part of manufacturing
practices. The FDA has effectively implemented these in various other
contexts, including food production25 ' and drug252  and device
development.253 These manufacturing practices would identify general
constructs for personnel, grounds, facilities, equipment, processes, and
controls, warehouse conditions, and distribution. The FDA would rely on
these when investigating and inspecting a particular e-cigarette facility, and
they would support enforcement action against violations.
247 Reporting Harmful Constituents, supra note 88, at 2.
2 4 8 See 21 C.F.R. § 101.9 (2011).
Id. § 101.36 (2011).
250 21 U.S.C. § 387g (2006).
251 21 C.F.R. § 110 (2011).
Id. §§ 210-211.
253 Id. § 820. This is called Quality System Regulation (QSR) in the device realm.
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D. Congressional Additive Amendments
In order to address concerns about the allure of e-cigarettes to children
under the age of 18, Congress should consider amending provisions in the
TCA that ban additives in cigarettes by broadening their coverage to
254encompass e-cigarettes. As written, the ban applies only to cigarettes,
leaving e-cigarettes and various other products free to incorporate flavoring
that may attract younger users. Likewise, legislation targeted toward e-
cigarette marketing and advertising would also assist to curb the appeal and
availability to adolescents and youth. However, the political will must exist
to make such a change at the legislative level. Based on the nearly ten years
it took Congress to enact the TCA, legislative fixes are not the primary or
ideal means of enhancing regulation.
E. A Role for State and Local Authorities to Restrict Use and Sale
States and local governments can play a role as well, in parallel with
FDA efforts to bolster regulation of e-cigarettes. A distinctive feature of the
TCA is the broad latitude expressly preserved to state and local authority to
regulate tobacco products. 2 55 Congress took pains not to limit authority of
federal agencies, states, or Indian tribes to "enact, adopt, promulgate, and
enforce any law, rule, regulation, or other measure" that "is in addition to, or
more stringent than, requirements [under the TCA], including a law, rule,
regulation, or other measure relating to or prohibiting the sale, distribution,
possession, exposure to, access to, advertising and promotion of, or use of
tobacco."256 The preemption clause directly following the preservation
clause does set bounds to this, in that federal requirements regarding product
standards, pre-market review, adulteration, misbranding, labeling,
registration, good manufacturing standards, and modified-risk tobacco
products preempt state and local requirements that are different from, or in
addition to, the federal requirements.257
This preservation will be essential to the states and localities as the
FDA rolls out regulations. It leaves much room for restrictions crafted more
25421USC 38ga()A(20)255 21 U.S.C. § 387g(a)(1)(A) (2006).
255 21 U.S.C. Id. § 387p(a)(1) (2006).
256 Id. § 387p(a)(1).
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specifically to the geographic location and local political environment.25 8
State and local regulatory efforts will likely continue to focus on smoking
bans and restrictions on promotional activities.259 Proactively assessing and
characterizing e-cigarette use, distribution, and promotion as part of state
and local efforts would be a valuable step. Specifically, authorities should
take care in drafting smoking bans to include e-cigarettes.
Thirty-nine states and 3,671 municipalities already have laws in place
restricting or prohibiting smoking in public places and workplaces.260
However, the laws were drafted with cigarettes and traditional tobacco
products in mind. Many specifically use the word "smoke" or "smoking" to
define the restricted or prohibited action. States must be careful to draft
relevant laws to explicitly include e-cigarettes if the intent is to prohibit or
restrict that action in addition to traditional means of smoking. For example,
New Jersey has become the first state to amend its public smoking laws to
include electronic cigarettes. The New Jersey Smoke-Free Air Act
(amended in 2010) prohibits smoking in indoor public places, workplaces,
and in buildings or grounds of any public or nonpublic elementary or
secondary school.26 1 It defines "smoking" as encompassing "the inhaling or
exhaling of smoke or vapor from an electronic smoking device" 262 and
defines "electronic smoking device" as "an electronic device that can be
used to deliver nicotine or other substances to the person inhaling from the
device, including, but not limited to, an electronic cigarette, cigar, cigarillo,
or pipe."2 63 Likewise, Somerset, Massachusetts; King County, Washington;
Madison County, Kentucky; Suffolk County, New York; Cattaraugus
County, New York; Savannah, Georgia; and San Francisco, California have
passed ordinances explicitly including e-cigarettes within the scope of their
258 For a discussion of state and local oversight opportunities under the TCA, see Leslie
Zellers & Ian McLaughlin, State and Local Policy as a Tool to Complement and Supplement
the FDA Law, 2 HASTINGS SCI. & TECH. L.J. 117 (2010).
259 See, e.g., id.
260 Overview List-How Many Smokefree Laws?, AM. NONSMOKERS' RIGHTS FOUND.,
http://www.no-smoke.org/pdf/mediaordlist.pdf (last updated Apr. 5, 2013). For a discussion
of state and local laws regarding smoking and their lack of application to electronic
cigarettes, see Daniel F. Hardin, Blowing Electronic Smoke: Electronic Cigarettes,
Regulation, and Protecting the Public Health, 2011 U. ILL. J.L. TECH. & POL'Y 433.
261 N.J. STAT. ANN. § 26:31-58 (West 2011).
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smoking bans.2 6
Various jurisdictions, both states and municipalities, have also enacted
laws requiring licenses to sell e-cigarettes and banning sales to minors. 2 65
Others are under consideration.26 6 States and local governments should
assess their current smoking bans and other restrictions and decide whether
to amend the language to include e-cigarettes. The political will and regional
differences in views on smoking will drive these efforts.
CONCLUSION
The ever-rising hype and consumption of e-cigarettes is an opportunity
to examine, interpret, and apply legislation governing tobacco products, as
well as reassess the scope of drug and medical device regulation. The
success of the e-cigarette industry signals the proliferation of a product
containing a highly addictive chemical that currently evades regulation in
light of recent case precedent and confusion regarding the scope of recently
enacted legislation. If the public health is to be adequately protected, the
FDA must initiate widespread investigations of product claims and
representations made by the manufacturers that frame e-cigarettes as
therapeutic products, as well as utilize the arsenal of statutory authority
provided in the TCA. This Article, through historical exploration,
comparative assessment, and statutory, regulatory, and case law
interpretation and analysis argues that there is a feasible approach to
strengthening regulation of e-cigarettes under the current statutory
framework. This approach includes increased scrutiny of manufacturer and
distributor claims for therapeutic intent triggering drug or medical device
provisions, examination of actual consumer use of e-cigarette products,
application of the new tobacco product and modified-risk tobacco product
provisions, and additional regulatory movements from the FDA to foster
uniformity and standardization, quality control, and access to product
information.
264 Karen Blumenfeld, Electronic Cigarettes (E-Cigarettes), GLOBAL ADVISORS ON
SMOKEFREE POLICY (Feb. 1, 2013) 1-2, http://www.njgasp.org/E-Cigs-White-Paper.pdf.
265 Id. New York recently enacted such a law, which also bans e-cigarettes use within
100 feet of a public or private school. Glenn Bain, Gov. Cuomo Signs Two Laws to Protect
Children from Nicotine Addiction; One of the Measures Bans the Sale of Electronic
Cigarettes to Youth Under the Age of 18, N.Y. DAILY NEWS (Sept. 5, 2012, 6:01 PM),
http://www.nydailynews.com/new-york/gov-cuomo-signs-laws-protect-children-nicotine-
addiction-measures-bans-sale-electronic-cigarettes-youth-age-I 8-article-1.1152718.
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